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2. ABSTRACT 
Barrett's oesophagus (BE) is a common premalignant condition to oesophageal 
adenocarcinoma (EAC). A previous genome-wide association study (GWAS) identified 
BE susceptibility Single Nucleotide Polymorphisms (SNPs) on chromosome 6p21, 
within the HLA region, and16q23, where the closest protein-coding gene was FOXF1.  
The replication study outlined in this thesis aimed to identify possible additional 
variants that did not reach genome-wide significance in the GWAS, in up to 10,158 BE 
patients and 21,062 controls. Meta-analysis of the data identified two further BE 
susceptibility SNPs: rs3072 (2p24.1; OR=1.14; 95%CI 1.09-1.18; P=1.8×10−11); and 
rs2701108 (12q24.21; OR=0.90; 95%CI 0.86-0.93; P=7.5×10−9). The two closest 
protein-coding genes, and most likely functional targets, are the bone morphogenetic 
protein pathway ligand GDF7 (rs3072) and TBX5 (rs2701108).  
A second GWAS of combined BE and EAC cases was recently published, analysing a 
total of 922,031 SNPs, where 87 of 94 associated SNPs with P<1×10−4 were selected 
for further replication, identified four SNPs (three loci) with BE/EAC risk in CRTC1 and 
BARX1 and within 100kb of FOXP1. Our data supported three of the BE/EAC-
associated SNPs and meta-analysis of all 87 SNPs detected a further susceptibility 
locus, rs3784262, near ALDH1A2 (OR=0.90, 95%CI 0.87-0.93, P=3.72×10−9).  
Overall, two novel BE susceptibility loci have been identified and data has been 
provided to support three previously identified BE/EAC SNPs and one additional 
BE/EAC locus. To date, genes implicated in BE susceptibility appear to encode 
transcription factors involved in thoracic, diaphragmatic and oesophageal development 
or inflammatory response proteins.  
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7. INTRODUCTION 
Barrett’s Oesophagus (BE; OMIM 614266) is a common premalignant condition, 
affecting up to 2% of the general population in the Western world [7], and arises from 
the transition of cells from normal squamous epithelium to columnar epithelium. It was 
first described by Dr Norman Rupert Barrett in 1950 [8]. BE is a precursor to 
Oesophageal Adenocarcinoma (EAC) and has been shown to follow a metaplasia (BE) 
– dysplasia (presence of abnormal cells within BE) - adenocarcinoma sequence (MCS) 
[9-11]. One risk factor for BE is reflux, potentially leading to oesophagitis (inflammation 
of the oesophagus). It is predicted that 10% of those with oesophagitis will go on to 
develop BE, where short segment BE (SSBE; <3cm) is more prevalent (8-20%) than 
long segment BE (LSBE; >3cm), with just 1% prevalence. BE patients have a 2-24% 
risk of developing high grade dysplasia (HGD), and a 2-5% risk of developing EAC [11]. 
Whilst patients with BE and HGD have a 40-50% risk of developing EAC within 5 years 
[12]. The incidence of EAC has been rising by 3% each year for the last 30 years and 
is the fifth most common cancer in the UK [13]. 
7.1 THE OESOPHAGUS 
The oesophagus is a muscular tube, measuring between 18-25cm in humans, through 
which food passes from the mouth to the stomach, aided by peristalsis. Two sphincters 
are present in the upper and lower ends of the oesophagus (upper oesophageal 
sphincter (UOS) and lower oesophageal sphincter (LOS)). The two sphincters act as 
barriers and prevent backflow of food and/or stomach acid. Food passes through the 
oesophagus, past the gastro-oesophageal junction (GEJ) and into the stomach. The 
wall of the oesophagus consists of four main layers: mucosa, submucosa, muscularis 
propria, and adventitia (Figure 7.1). The mucosa is composed of the stratified 
squamous epithelium, lamina propria and muscularis mucosa. The submucosa 
contains bloods vessels, nerves and glands. The muscularis propria consists of 
skeletal (upper muscularis propria) and smooth (lower muscularis propria) muscle 
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fibres; where grouping of both muscle types is known as the transition zone. The 
adventitia is an external fibrous layer composed of loose connective tissue. 
Oesophageal mucosa is pale pink in colour in contrast with the darker gastric mucosa 
present in the stomach. The Z-line is the term used to describe the position at which 
the two mucosa meet. The oesophagus does not have a serous membrane, unlike the 
rest of the gastrointestinal (GI) tract. It is thought that the absence of this layer allows 
oesophageal cancers to spread more easily. 
7.2 PREVALENCE OF BE 
There is a large variation in the prevalence of BE across the globe, particularly when 
comparing Western to Eastern worlds. The majority of data collected for BE prevalence 
is based on patients undergoing endoscopy procedures, and so are not a true 
reflection of prevalence, as BE cases can be asymptomatic [14]. However, some 
studies have based their research on a random selection of the general population; 
Hayeck et al (2010) estimated the prevalence of BE in the USA at 5.6% [15], 
Ronkainen et al (2005) estimated BE prevalence in Sweden at 1.6% [16], and Zagari et 
al (2008) estimated the prevalence of BE in Italy at 1.3% [17]. The true prevalence of 
BE worldwide is unknown due to asymptomatic cases and a lack of resources in some 
Transition 
zone 
Stratified squamous 
epithelium 
Lamina propria 
Muscularis 
mucosa 
Submucosa 
Muscularis propria 
Adventitia 
Mucosa 
Artery 
Vein 
Nerve 
Figure 7.1: Oesophageal Wall Structure. The oesophageal wall is composed of four main sections: 
mucosa, submucosa, muscularis propria and adventitia. The mucosa contains the stratified squamous 
epithelium, lamina propria and muscularis mucosa. The submucosa contains bloods vessels, nerves 
and glands. The muscularis propria consists of skeletal (upper) and smooth (lower) muscle fibres; 
there is combination of both muscle types in the transition zone. The adventitia is an external fibrous 
layer composed of loose connective tissue. 
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countries, however it has been estimated between 1.6-3% [10]. 
7.3 BE DIAGNOSIS 
BE is initially diagnosed by endoscopy, which allows the measurement of the length of 
BE segment. A change in colour of the lining of the lower oesophagus from its normal 
pale pink (stratified squamous epithelium) to a red colour (columnar epithelium) 
suggests that BE has developed. The junction of these two epithelia is called the Z-line. 
If this colour change is present then biopsies will be taken from various sites in the 
oesophagus. The biopsies will be histologically examined for the characteristic 
columnar cells to confirm diagnosis. When examining the biopsies, the histologist will 
also look for the presence of goblet cells (known as Intestinal Metaplasia; IM) and any 
signs of dysplasia (the presence of abnormal, precancerous cells).  
The degree of dysplasia in BE can be classed as one of the following: 
1. Negative for dysplasia; presence of mild abnormalities (e.g. nuclear 
enlargement, crowding) usually confined to the lower glands, which can be 
misinterpreted as dysplasia. 
2. Indefinite dysplasia; where the significance of any observed dysplasia is 
uncertain. For example, the nuclei may be enlarged but uniform in size and 
shape, unlike that seen in dysplasia. 
3. Low grade dysplasia (LGD); the presence of dysplastic nuclei that are located in 
the base of the cell. 
4. High grade dysplasia (HGD); presence of inconsistent dysplastic nuclei with 
loss of nuclear polarity confined to the mucosa, without crossing the basement 
membrane. 
5. Intramucosal adenocarcinoma; where the dysplasia crosses the basement 
membrane and invades the lamina propria (see Figure 7.1). 
6. Invasive adenocarcinoma; where dysplasia reaches deeper into the tissue and 
invades the muscularis mucosa (see Figure 7.1) [7, 18-20]. 
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7.4 INCREASED RISK FACTORS ASSOCIATED WITH BE 
Risk factors associated with BE include gender, age, ethnicity, smoking, obesity (waist-
hip ratio; WHR) and gastro-oesophageal reflux disease (GERD). 
7.4.1 Gender 
BE is more common in males (with 2:1 male:female ratio), possibly due to a protective 
effect, related to sex-specific hormone seen in premenopausal women (possibly 
oestrogen) [18, 21, 22]. 
7.4.2 Age and Ethnicity 
BE is more common in individuals over 50 years of age and in those of white 
Caucasian origin [23].  
7.4.3 Smoking 
There is conflicting evidence about the association between smoking and BE. Kubo et 
al (2009) [24] conclude that there was no association, however their sample size was 
small (320 BE cases, 316 GERD cases and 317 population controls) which limits the 
power to detect an association. More recently, Balasubramanian et al (2013) [25] 
tested the association between smoking and BE with a case sample size of 1,056 and 
concluded that smoking was an independent risk factor for BE, which significantly 
increases with the intensity of smoking and that stopping for 20 years or more reduces 
this risk. 
7.4.4 Obesity – Body Mass Index (BMI) and Waist-Hip Ratio (WHR) 
Similarly to smoking, there is some conflicting evidence over the association between 
obesity and BE, although the majority of studies do confirm a link between the two [26]. 
Kamat et al (2009) [27] showed that there was a small statistically significant 
association between obesity and BE. However, Kubo et al (2013) [28] concluded that 
there was not an association between increased BMI and BE, rather that there was an 
association with larger waist circumference. Similar studies have confirmed that 
increased waist-hip ratio (WHR) is a risk factor, rather than increased BMI, for 
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developing BE, particularly LSBE [29, 30]. It has been shown that as women reach 
menopause, they tend to gain weight, and so are at more risk of developing BE later in 
life compared to men [21].  
7.4.5 Gastro-oesophageal Reflux Disease (GERD) 
One of the main risk factors is GERD, which is usually caused by the failure of the 
lower oesophageal sphincter (LOS), resulting in stomach acid entering the oesophagus 
causing mucosal damage [31, 32].  
Risk factors for GERD include hiatus hernia, where the upper part of the stomach 
protrudes into the thorax through a weakened diaphragm [33]; obesity; factors that 
increase gastrin production and acidity, for example Zollinger-Ellison syndrome [34] 
and hypercalcaemia [35]; and factors that result in oesophageal dysmotility, such as 
systemic sclerosis [36].  
Diagnosis of GERD is usually given when the typical symptoms are present, such as 
heartburn and regurgitation [37]. A 24-hour pH-monitoring device may be used to 
confirm diagnosis, which sits inside the patient’s oesophagus and records the pH level 
over a 24-hour period. An endoscopy may be requested if further investigation is 
needed. 
It is important to control the amount of acid released into the oesophagus to prevent 
possible complications, such as oesophagitis (inflammation of the oesophageal lining) 
and BE. Treatment for GERD includes lifestyle changes, medication and surgery. 
Weight loss, quitting smoking and removal of alcohol from the diet appears to reduce 
reflux symptoms, as does moderate exercise and avoiding specific foods that increase 
stomach acid (such as coffee, chocolate and spicy foods).  Medications include Proton 
Pump Inhibitors (PPIs), H2 receptor blockers and antacids [38, 39]. Nissen 
fundoplication, a surgical procedure, is an option for those who respond well to 
medication but don’t want to continue it long-term or for those who have side effects to 
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medication (mainly diarrhea, fractures or drug interactions), and involves wrapping of 
the upper section of the stomach around the LOS to strengthen it. 
Between 5-10% of patients with GERD go on to develop BE [6], indicating other 
genetic and/or environmental factors associated with BE [7, 24, 29, 40-47]. 
7.5 DECREASED RISK FACTORS ASSOCIATED WITH BE 
Two basic factors associated with decreased risk of BE are consumption of a good diet 
and nutrients. Other factors associated with decreased BE risk are Helicobacter pylori 
(H.pylori) infection and the use of Aspirin and Non-Steroidal Anti-Inflammatory Drugs 
(NSAIDs). A large trial is currently assessing the long-term value of aspirin preventing 
BE developing into cancer. 
7.5.1 Diet and Nutrient Intake 
A study published by Kubo et al (2009) [42] found that higher intakes of omega-3-fatty-
acids, polyunsaturated fat and fibre from various sources, including fruits and 
vegetables were all associated with a lower risk of BE. They also found that higher 
meat intakes were associated with a lower risk of long-segment BE. However, higher 
trans-fat (a type of unsaturated fat) intakes were associated with increased BE risk. 
Nutrient intake has also been associated with a reduction in BE risk. Kubo et al (2008) 
[41] showed that high intakes of vitamin C, beta-carotene, and vitamin E were all 
inversely associated with BE risk, with the latter being the most significant association. 
7.5.2 Helicobacter pylori Infection 
H.pylori is a gram-negative microaerophilic bacterium found in the stomach, and is 
associated with decreased BE risk. It is estimated that >50% of the world's population 
carry H.pylori in their upper GI tract. The infection is more prevalent in developing 
countries, and is decreasing in Western countries. It is thought that the bacterium 
reduces BE risk via factors which appear to reduce gastric acid [48]. Various studies 
investigating the effects of H.pylori have shown that there is considerable decreased 
risk of BE in patients who carry H.pylori. A study completed by Corley et al (2008) [49] 
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showed that BE patients were less likely to have antibodies for H.pylori (OR=0.42) than 
population controls. They also showed that the inverse association was stronger 
among those with BMIs<25 (OR=0.03) compared to those with BMIs>30 (OR=0.43). 
Similarly, a study completed by Anderson et al (2008) [50] found that those positive for 
H.pylori were inversely associated with BE (OR=0.41). However, they also showed that 
the inverse associations between the presence of the bacterium and BE remained in 
patients who did not experience reflux symptoms, suggesting that the bacterium acts 
via more than one mechanism to reduce BE risk. 
7.5.3 Aspirin and Non-Steroidal Anti-Inflammatory Drugs 
There are conflicting reports about the protective effects of Aspirin and NSAID use. 
Anderson et al (2006) [51] showed that the use of these drugs were associated with a 
reduced risk of BE, with OR=0.53 for Aspirin and OR=0.40 for NSAIDs. However, a 
similar study published by Wang et al (2010) [52] suggested that the drugs might act 
after the formation of BE in the inflammation-metaplasia-dysplasia-adenocarcinoma 
sequence, and hence protect against EAC instead. 
7.6 TREATMENT AND PROGNOSIS 
7.6.1 Treatment 
Patients with reflux symptoms will more than likely opt to take either over-the-counter 
antacids or prescribed PPIs. These drugs act by preventing cells in the lining of the 
stomach from producing too much acid. Treatment for BE depends on the stage of 
disease. Patients with non-dysplastic or LGD BE are more likely to undergo 
endoscopic surveillance, where an endoscopy procedure is carried out every two years 
with the aim to catch possible progression of the disease early [53]. There are surgical 
procedures available for BE patients who have LGD or HGD, including Nissen 
fundoplication, endoscopic mucosal resection (EMR), endoscopic ablative therapy 
(including photodynamic therapy (PDT), argon plasma coagulation (APC), cryotherapy, 
and radio-frequency ablation (RFA)), and oesophagectomy to name a few. Nissen 
fundoplication is a surgical procedure used to treat GERD and hiatus hernia and 
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involves wrapping the upper part of the stomach (fundus) around the lower 
oesophagus. The idea behind the procedure is to mimic the function of the LOS to 
prevent acid reflux. EMR involves the endoscopic removal of the affected tissue, which 
can then be histologically examined [54]. Endoscopic ablative therapy involves the 
destruction of the effected tissue, which is then usually followed by repopulation with 
normal squamous epithelia in a non-acidic environment [7, 19, 55, 56]. The issue with 
this technique is ensuring that all BE tissue is ablated. An oesophagectomy is usually 
employed if patients have HGD or EAC, and involves the removal of all or part of the 
oesophagus. However, it is associated with high mortality and morbidity rates [7, 19, 
57].  
7.6.2 Prognosis 
It is important to limit the amount of acid entering the oesophagus in order to prevent 
an increase in BE segment size. This can be achieved via the treatment methods 
outlined above (section 7.6.1). An increase in BE segment length increases the chance 
of developing EAC. Only 2-5% of BE patients progress to EAC (~5% lifetime risk in 
men and ~3% in women), which has a high mortality rate [6, 7, 20, 58, 59]. One study 
has shown that BE patients die more commonly of bronchopneumonia and ischaemic 
heart disease rather than EAC [59]. BE cannot be cured unless all affected tissue has 
been removed. It has also been shown that BE can regress, although short segment 
BE is more likely to regress than long segment BE, as were those treated surgically [60, 
61]. 
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7.7 CELLULAR ORIGIN 
BE is a disorder which effects the lower section of the oesophagus and causes the 
cells to change from normal squamous epithelial cells to columnar cells (IM) due to 
prolonged acid exposure. The inability to observe this process in vivo and a lack of 
animal models has meant that the true cellular origin of BE has yet to be conclusively 
established [62].   
7.7.1 Hypotheses 
Initial studies suggested the cells migrate upwards from the stomach, specifically the 
gastro-oesophageal junction (GEJ) [63], however this theory was later discounted 
when animal models suggested that the cells arose within the oesophagus itself [64-
66]. Many hypotheses for the origin of the columnar cells have since been based on 
the latter theory. A diagrammatic overview of the hypotheses can be seen in Figure 7.2 
(adapted from Phillips et al (2011) [6]). The first hypothesis was that a stem cell, 
located in the basal layer of the squamous epithelium, was reprogrammed to produce 
columnar cells rather than the normal squamous cells [67, 68]. The second hypothesis 
described the location of the stem cell inside the oesophageal gland duct, which 
Figure 7.2: Hypotheses for BE Cellular Origin. (A) reprogramming of a 
stem cell, (B) Proliferation and migration of cells from the glands after acid 
exposure, (C) trans-differentiation of squamous epithelia to columnar 
epithelia, (D) external signals induced by acid, (E) mesenchymal to 
epithelial  transition. Figure adapted from Phillips et al 2011 [6]. 
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connects to the surface of the oesophagus. It was hypothesised that chronic reflux 
caused exposure of the stem cell which then initiated migration and differentiation of 
cells, from the duct, to columnar cells in order to replace the effected normal epithelium 
[23, 69-71]. The third hypothesis described the trans-differentiation [72] of normal 
squamous cells to columnar cells, caused by an acidic environment. It was 
hypothesised that this occurred through an epigenetic effect where the lining of the 
oesophagus reverts back to the cells present in early embryogenesis (columnar cells) 
before the trans-differentiation of these cells to mature squamous cells [73-75]. The 
fourth hypothesis described indirect effects on the lining of the oesophagus, specifically, 
changes to the epithelial layer caused by regulatory signals produced by stromal cells 
in the submucosa [76].  The final hypothesis suggests that the columnar cells arise 
from stromal cells directly via a mesenchymal-to-epithelial transition [69]. 
7.7.2 Gastro-Oesophageal Junction Origin 
More recent studies have proposed that BE does in fact originate from the GEJ [77, 78]. 
In particular, a study published by Lavery et al (2014) [79], found that although 
segments of BE contained both intestinal (usually  found in the intestine) and gastric 
cells (usually found in the stomach), the glands themselves were more similar to the 
Figure 7.3: Stomach compartments and a diagrammatic view of an oesophageal gland duct. The 
oesophageal gland ducts (B) are similar to those found in the Pylorus of the stomach (A). The stem cells 
are located within the neck of the gland and cells migrate upwards towards the surface and down 
towards the case of the duct (bidirectional migration). 
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pyloric glands found at the base of the stomach (Figure 7.3A). Both pyloric and 
Barrett’s glands have the same type of structure (Figure 7.3B). The stem cells in both 
glands are located in the neck, whereas in intestinal glands they are located in the 
base. They also found that BE glands were clonal, containing multiple multipotent stem 
cells, which were capable of differentiating into both intestinal and gastric cell lineages. 
When undertaking experiments using Ki67 and iododeoxyuridine (IdU) labelling, they 
found that cells moved both up to the surface and down to the base of the crypt from 
the neck, known as bidirectional migration (also seen in the pylorus glands). 
7.8 MOLECULAR MECHANISMS 
7.8.1 Pathways 
Mucosal damage (e.g. reflux) is thought to result in the activation of molecular 
mechanisms involved in embryogenesis and/or adult tissue. Pathways thought to be 
involved are the Hedgehog (HH) [76, 80-84], Transforming Growth Factor β (TGFβ) [85, 
86], Notch [80, 85, 86] and Mitogen-Activated Protein Kinase (MAPK) [87, 88] 
signalling pathways. 
7.8.1.1 Hedgehog Signalling Pathway 
The HH signalling pathway, of which there are three homologues: Desert (DHH), Indian 
(IHH), and Sonic (SHH), is important in normal embryo development. It plays an 
important role in the early oesophagus (columnar epithelia) but then diminishes in the 
mature oesophagus (squamous epithelia), resulting in the absence of the HH ligand on 
the epithelial surface [76, 81, 82]. Whilst this is the case in the normal oesophagus, 
some studies have shown that in BE, both SHH and IHH are up regulated. Wang et al 
(2010) [84] also found that the HH target genes Ptch1 (Patched 1) and BMP4 (Bone 
Morphogenetic Protein 4) were expressed in the stroma of BE but not of the normal 
epithelia. They proposed that hedgehog ligand expression could contribute to BE 
through the stimulation of the target genes, which in turn, triggered the production of 
columnar epithelia [6, 84].  
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7.8.1.2 Transforming Growth Factor β (TGFβ) and Notch Signalling Pathway 
Both TGFβ and Notch signalling pathways are important in the developing embryo and 
adult tissues. The TGFβ pathway regulates multiple cellular processes, such as cell 
growth, differentiation and apoptosis. The Notch signalling pathway regulates cell-fate 
determination in the embryo and maintains homeostasis in the adult tissue [89]. A 
study published by Mendelson et al (2011) [86] discovered that a dysfunctional TGFβ 
signalling pathway was present in 5/10 BE cases and 17/22 EAC cases and that there 
was consistent activation of the Notch signalling pathway in EAC.  
7.8.1.3 Mitogen-Activated Protein Kinase (MAPK) Signalling Pathway  
The MAPK signalling pathway regulates multiple cellular processes including 
proliferation, differentiation and apoptosis. Studies have shown that these pathways 
can be activated by reflux exposure in Barrett’s cell lines [87, 88]. When the cells were 
exposed to acid, proliferation and survival increased, whilst apoptosis decreased, 
suggesting that acid exposure might contribute to the metaplasia-dysplasia-carcinoma 
sequence seen in BE, through activation of MAPK pathways [87]. 
7.8.2 Chromosome Instability – Somatic Variations 
Chromosome instability in BE has been illustrated in various studies [90-92]. They 
revealed that copy number variations (CNVs) and loss of heterozygosity (LOH) 
(particularly of chromosome arms 9p and 17p) increased in frequency and size 
between early (non-dysplastic and LGD) and late (HGD and carcinoma) stage BE 
(P<0.001). Li et al (2008) [90] found that chr9p had large regions of copy loss and LOH 
spanning most of the arm in patients with early-stage BE. Three statistically significant 
LOH events seen on chr9p spanned 9.0-12.1Mb, 20.5-25.0Mb and 28.5-30.5Mb. Copy 
loss of the FHIT and WWOX loci were also seen in patients with early-stage BE. In 
addition, patients with early-stage BE also had statistically significant small 
abnormalities, containing multiple genes, such as copy gains on 8q24.3 and 10q22.1. 
In contrast, patients with late-stage BE had copy loss or LOH of whole chromosome 
arms, such as 3p, 5p and 5q, 9p, 13p and 13q, 17p and 18q. 
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Similarly, Paulson et al (2009) [91] found that the most common region of CNVs in 
patients with early-stage BE was on chromosome 9p, specifically loss of the p16 locus 
and two other areas (10.4Mb-11.8Mb and 25.5Mb-27.5Mb). Chromosomes 1 and 8 
also had copy number losses. Paulson et al (2009) [91] concluded that patients with 
CNVs involving >70Mbp were at increased risk of progression to DNA abnormalities 
and/or EAC (P=0.0047) [91]. 
Many functional candidate genes for BE progression have been identified, including the 
highly conserved homeobox (HOX) gene family (specifically, Caudal type homeobox 
(Cdx) 1 and Cdx2), tumour suppressor genes (p53, p63, p16 and APC (Adenomatous 
polyposis coli)), and other speculative genes. These genes have been implicated in 
small replication studies, but have not been assigned genome-wide statistical 
significance. More recently however, Genome-Wide Association Studies (GWAS) have 
identified two statistically significant BE susceptibility SNPs [2] and four statistically 
significant BE/EAC associated SNPs [3]. 
7.8.2.1 Cdx1 and Cdx2 
HOX genes encode developmental transcription factors important for development [93-
95]. Cdx1 and Cdx2, predominantly expressed in the small intestine and colon, are 
believed to direct the development and differentiation of the columnar epithelium [95, 
96]. Due to their role in the intestine, it was thought they might have a role in the 
development of BE [97]. This theory has recently been supported via a study published 
by Ren et al (2014) [47], which has shown that five SNPs within Cdx1 and three within 
Cdx2 were associated with BE susceptibility (P<0.05).  
7.8.2.2 Tumour Suppressor Genes: p53, p63, p16/CDKN2A and APC 
Loss of p53 has long been established as a key step in oncogenesis, whilst mutations 
within exons 5-8 of this gene are seen as late steps within the MCS. p53 mutations are 
seen in 5–10% of cases with unspecified dysplasia, 65% of patients with LGD, 75% of 
patients with HGD, and 50–90% of patients with EAC [11, 98]. On the other hand, p63 
(a member of the p53 family of transcription factors) mutations are seen in the early 
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stages of BE [99, 100]. In the normal squamous epithelium, p63 is absent. In columnar 
epithelium, however, p63 is expressed in the basal layer. The importance of this gene 
during oesophageal development has been shown through the use of p63 knockout 
mice, where they developed a columnar epithelium rather than squamous in the 
oesophagus [101]. p16 (also known as cyclin-dependent kinase inhibitor 2A), is known 
for its importance in cell cycle regulation. This tumour suppressor protein has been 
shown to be inactivated in BE and EAC through the hyper-methylation or mutation of 
the CDKN2A promoter [102, 103]. APC mutations have long been established in 
colorectal cancer. Mutations in this gene have also been implicated in EAC, where 
there is increased LOH in late-stage BE [11, 104]. It has been hypothesized by 
Jankowski et al (1999) [11] that this may lead to reduced β-catenin degradation, 
increasing β-catenin levels, and facilitating epithelial-to-mesenchymal (EMT) transition 
via transcription factors [105]. 
7.8.2.3 Other BE Susceptibility Genes 
Replication studies have identified candidate polymorphisms associated with BE, 
including: IL-1 [106]; Myo9B [44]; EGR [107]; TGFβ [45]; IL-18 receptor-accessory 
protein and the IL-18 promoter [108]; PXR [109]; IGF1, GHR, IGF1R [43, 110]; IL-12B 
[111]; NQO1 [112]; GSTP1 [40]; CCND1 [113]; XRCC1 [114]; IL-10 [115] and GTSP1 
[116]. SNPs near or within these genes have been associated with BE susceptibility 
loci in small replication studies, consisting of 22-257 cases and 94-455 controls. 
7.8.3 Chromosome Instability – Germline Variations 
Three germline variations were identified by Orloff et al in 2011 [46]. The three genes 
associated with BE/EAC (P<0.001) were; MSR1 (Macrophage Scavenger Receptor 1), 
ASCC1 (activating signal co-integrator 1 complex subunit 1), and CTHRC1 (collagen 
triple-helix repeat-containing 1) [46]. MSR1 was most frequently mutated with 8/116 
patients (6.9%) in the initial study and 2/58 patients (3.4%) in the replication study.  
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7.8.4 Single-Nucleotide Polymorphisms identified via Genome-Wide Association 
Studies 
Genome-Wide Association Studies examine many common genetic variants in 
individuals to see if any variant is associated with a trait, for example BE. The first 
GWAS (comprising 7,838 cases and 17,997 controls) published in 2012 by Su et al 
(2012) [2] identified two SNPs, one near FOXF1 and another within the MHC region, to 
be associated with BE [2]. The FOXF1 gene encodes the transcription factor FOXF1 
(Forkhead Box F1) protein. FOXF1 is important in the development of pulmonary 
mesenchyme (the embryonic tissue from which blood vessels of the lung arise) and the 
development of the GI tract. The gene-rich MHC region is important for immune system 
regulation. Defects within MHC genes can result in autoimmune disorders, such as 
multiple sclerosis and inflammatory bowel disease [117, 118]. 
A second GWAS (comprising 2,363 EAC cases, 3,116 BE cases and 10,060 controls) 
identified four SNPs (three loci) to be associated with BE and EAC (combined) located 
within CRTC1 and BARX1 and near FOXP1 [3]. CRTC1 encodes the CREB-regulated 
transcription coactivator 1 (CRTC1) protein. BARX1 encodes a member of the Bar 
subclass of homeobox transcription factors, BARX homeobox 1 (BARX1) protein. 
BARX1 is thought to regulate differentiation of stomach epithelia via the WNT signalling 
pathway [119, 120]. FOXP1, a tumour suppressor gene, encodes a member of the 
FOX transcription factors, FOXP1. This particular transcriptional repressor is thought to 
be important in the specification and differentiation of the lung [121-123]. 
7.9 CLINICAL TRIALS 
Clinical trials provide important information and samples for disease research. There 
are currently two on-going UK-based trials for Oesophagitis, BE and EAC: ChOPIN 
and AspECT. 
7.9.1 Chemoprevention Of Premalignant Intestinal Neoplasia (ChOPIN) 
The ChOPIN study aims to assess both epigenetic and genetic changes that lead to 
pre-malignancy and cancer. The study has been devised in two parts; firstly, 
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biomarkers, array and assessment of clonal changes in pre-malignant mucosa and 
early cancer. Secondly, a GWAS to investigate inherited predisposition to oesophageal 
diseases. Each patient in the study is required to complete a patient history form which 
records information on height, weight, age, diet, smoking history, alcohol consumption 
and surgical procedures; all of which will be useful for performing sub-analyses.  
7.9.2 Aspirin and Esomeprazole Chemoprevention in Barrett's Metaplasia 
(AspECT) 
The AspECT study is investigating the use of both aspirin and PPI therapy. The study 
aims to investigate the benefits of acid suppression with low or high dose PPI 
(esomeprazole) with or without aspirin in reducing the risk of cancer and/or HGD in BE 
patients. It is also examining whether intervention with aspirin with or without PPI 
therapy results in decreased mortality rate. 
7.10 BARRETT’S OESOPHAGUS GENOME-WIDE ASSOCIATION STUDY 
The research completed for this thesis is a continuation of a previously published 
GWAS paper by Su et al (2012) [2]. The sample sets and how they were used in the 
previous paper is outlined below. Sample sets described below have been used in the 
replication study (current research) when undertaking meta-analyses. All phases 
consist of unrelated individuals of white Caucasian origin and each sample set is 
independent of one another.  
7.10.1 Samples 
7.10.1.1 Cases 
All cases were diagnosed with histologically-confirmed BE, accompanied with an 
endoscopy report. Cases in the Discovery Phase were recruited under the UK-based 
AspECT clinical trial [124]. Sample collection was in accordance with the British 
Society of Gastoenterology criteria [53], which is the standard practice for 
histopathologists in the UK and most of Europe. In the Discovery set, 90% of the 
samples had evidence of IM and so also met the American College of 
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Gastroenterology criteria used in the United States of America [57]. 
The UK, Irish and Dutch Replication Phases were acquired from the ChOPIN genetic 
study and the Esophageal Adenocarcinoma GenEtics (EAGLE) consortium [7].  
Discovery cases 
1,852 BE UK cases (80.3% male) from multiple NHS sites across the UK, collected 
under AspECT (Chief Investigator: J Jankowski). 
Stage 1: UK Replication 1 (UKREP1) cases 
1,105 BE patients (70.9% male, 0.3% not stated) from multiple NHS sites across the 
UK recruited under ChOPIN. 
Stage 2: Dutch Replication cases 
473 BE patients (74.0% male) were collected under ChOPIN from the University 
Medical Centre, Groningen. 
Stage 3: UK Replication 2 (UKREP2) cases 
1,765 BE cases (71.4% male, 0.6% not stated) collected from various NHS sites 
across the UK under ChOPIN.  
Stage 3: Irish Replication cases 
245 BE cases (64.1% male, 8.6% not stated) from St. James’s Hospital and Mater 
Misericordiae University Hospital, Dublin. 
Stage 3: BEACON Replication cases 
2398 cases (76.0% male) were collected as part of a GWAS study (BEAGESS). 
Samples were collected from sites in Australia (n=325), Europe (n=363) and North 
America (n=1710). 
7.10.1.2 Controls 
Controls for each phase were collected from various sources detailed below. 
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Discovery Controls 
5,172 population controls, part of the Wellcome Trust Case Control Consortium 2 
(WTCCC2; Chief Investigator: P Donnelly) set (50.4% male), made up of the 1958 
British Birth Cohort (58C) and the National Blood Service collections (UKBS).  
A total of 2,673 controls were selected from the 58C (also known as The National Child 
Development Study (NCDS)). The cohort was set up to follow the lives of 17,000 
people born in England, Scotland and Wales in a single week in March 1958. Each of 
the surviving cases were followed up at ages 7, 11, 16, 23, 33, 42, 46, 50 and 55 [125]. 
The remaining 2,499 controls consisted of blood donors recruited by the WTCCC in 
collaboration with the UK Blood Services [126]. 
Stage 1: UKREP1 controls 
A total of 6,819 controls (47.9% male) were used for UK Replication 1. 2,578 controls 
were part of People of the British Isles (PoBI; Chief Investigator: W Bodmer) and the 
remaining 4,241 controls were samples from the 58C that had not been used in the 
Discovery Phase. 
PoBI, funded by the Wellcome Trust, began collecting blood samples from 4,500 
people from rural populations throughout the British Isles in 2004 to examine genetic 
differences around the UK. A sub-section of the study is also investigating the inherited 
variation of facial features within the UK.  
Stage 2: Dutch Replication controls 
1,780 controls (59.2% male) provided by the University Medical Centre, Groningen. 
Stage 3: UKREP2 controls 
1,586 controls (45.2% male, 4.3% not stated) were collected under the Colorectal 
Tumour Gene Identification (CoRGI) Consortium (Chief Investigator: I Tomlinson). 
CORGI aims to identify genes that increase the risk of bowel cancer or non-cancerous 
tumours. The controls used in this study consist of individuals unaffected by cancer 
and without a family history of colorectal neoplasia [127]. 
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Stage 3: Irish Replication controls 
A total of 473 controls (35.1% 
male, 0.6% not stated) were 
provided by Trinity Biobank, 
Dublin. The Biobank was 
established in 2004 and 
facilitates processing, storage 
and distribution of specimens for 
research undertaken in Trinity 
College (St James’s Hospital). 
Stage 3: BEACON Replication 
controls 
A total sum of 2167 controls (78.6% 
male) were collected as part of a 
GWAS (BEAGESS). Samples 
were collected from sites in 
Australia (n=561), Europe (n=333) and North America (n=1273). 
7.10.2 SNP Selection 
In the Discovery Phase 521,744 SNPs were analysed. After analysis of the Discovery 
SNPs, only 100 with P<5×10-4 were taken forward to Stage 1 Replication. When 
combining the Stage 1 Replication data with the Discovery data, there were 16 SNPs 
with P<5×10-5. These 16 SNPs were taken forward to Stage 2 Replication. Once the 
Stage 2 data had been combined with Discovery and Stage 1, two SNPs reached 
genome-wide significance, with P<5×10-8. These 2 SNPs were further replicated in 
Stage 3 for validation, where both SNPs reached P<5×10-9 and were reported as BE 
susceptibility loci. An overview of sample sets and SNPs analysed can be seen in 
Figure 7.4 (adapted from Su et al (2012) [2]). 
Figure 7.4: Stages of the previous Genome-Wide 
Association Study paper.  Figure adapted from Su et al 
[2] 
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7.10.3 Ethical Considerations 
Written informed consent was obtained from all subjects. The ethics of the project were 
reviewed by the East London and the City Research Ethics Committee (04/Q0603/1). 
All UK studies were implemented with national ethics committee approval (MREC 
numbers: AspECT 04/Q0603/1; ChOPIN/IPOD 06/Q1603/07; HANDEL 09/H0505/23; 
and CORGI 06/Q1702/99). The Irish samples were collected with approval from the 
Research Ethics Committee Board of St. James’s Hospital. The Dutch replication 
samples were collected with approval from the ethics committee or institutional review 
board of all participating institutions. The BEACON/BEAGESS project obtained 
informed consent from all recruited participants, and was approved by the ethics 
boards of each participating institution. 
7.10.4 Genotyping  
7.10.4.1 Discovery Phase  
Genotyping was performed using the Illumina 660W-Quad array for cases and a 
custom Human 1.2M-Duo array for controls at the Wellcome Trust Sanger Institute 
(WTSI) [2].  
7.10.4.2 Stage 1  
UKREP1 genotyping was performed using the custom Illumina Infinium HD genotyping 
array, the Immunochip, at the WTSI [2]. 
7.10.4.3 Stage 2 
Dutch Replication samples were genotyped on the Illumina Immunochip but in two 
separate locations; the cases were genotyped at WTSI and the control samples were 
previously genotyped [128].  
7.10.4.4 Stage 3 
(a) Irish Replication: 168 cases were genotyped on the Illumina Immunochip at WTSI. 
rs9257809 and rs9936833 (the 2 SNPs taken forward to stage 3) were genotyped 
in 77 cases and all controls using competitive allele-specific PCR KASPar 
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chemistry (LGC Ltd, Hertfordshire, UK).  
(b) UKREP2: All samples were genotyped using KASPar competitive allele-specific 
PCR.  
(c) BEACON Replication: All samples were genotyped at the Fred Hutchinson Cancer 
Research Center (FHCRC) on the Illumina Omni1M Quad. 
7.11 INDIVIDUAL CONTRIBUTIONS FOR THE REPLICATION STUDY 
The Replication Study completed as part of this thesis is a continuation of the BE 
GWAS data published by Su et al (2012) [2].  
Since joining the BE research team (who published the GWAS in 2012) in February 
2013, four new sample cohorts have been collected and analysed for a specific set of 
SNPs. 
The research completed for both the BE GWAS and the Replication study was a 
collaborative project between researchers both nationwide and worldwide. Table 7.1 
shows the contributions of each individual involved in the BE Replication study.  
Whilst completing the BE Replication Study a paper analysing 87 SNPs, identifying 
four as novel BE/EAC-associated SNPs, was published [3]. It was decided to try to 
replicate the 87 SNPs published by Levine et al (2013) [3]. Table 7.2 shows the 
individual contributions for the Levine replication study.  
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Table 7.1: Contributions of individuals at each stage of the BE Replication study.  
Section Researcher Comments
Collection and Extraction of 
Replication Phase 2 case and 
control DNA
Available from previous 
publication [1]
Replication Phase 2 SNP selection Claire Palles, Janusz Jankowski, Ian Tomlinson
Sequenom iPLEX design Claire Palles
Sequenom iPLEX genotyping Wellcome Trust Sanger Institute
Replication Phase 3 SNP selection Claire Palles, Janusz Jankowski, Ian Tomlinson
Processing of ChOPIN/AspECT 
samples for screening
Laura Chegwidden, Barbara 
Zietek, Neera Maroo, Laura Gay, 
Manoj Nanji
Time Periods: Laura Chegwidden: 
Feb’13-Feb’14; Barbara Zietek: 
Jan'12-Apr’13; Neera Maroo: 
Jan'12-Dec'12; Laura Gay: '08-'12; 
Manoj Nanji: '06-'09
UK Replication 3 case collection, 
processing and storage
Laura Chegwidden, Barbara 
Zietek, Neera Maroo, Laura Gay, 
Manoj Nanji
610 cases by Laura Chegwidden; 
387 cases by Barbara Zietek, 
Neera Maroo, Laura Gay and 
Manoj Nanji
Phenotype Classification and Patient 
History Form input for UK 
Replication 3.
Laura Chegwidden and Laura Gay
BE and IM Classification for 610 
cases by Laura Chegwidden; 387 
cases by Laura Gay
UK Replication 3 case DNA 
extraction
Laura Chegwidden, Claire Palles 
and John Findlay
610 cases by Laura Chegwidden; 
387 by Claire Palles and John 
Findlay
UK Replication 3 control DNA 
extraction
Elinor Sawyer and Rebecca 
Roylance
UK Replication 3 case genotyping Laura Chegwidden, Claire Palles and John Findlay
610 cases by Laura Chegwidden; 
387 by Claire Palles and John 
Findlay
UK Replication 3 control genotyping Claire Palles and Sarah Briggs 4 SNPs by Claire Palles, 3 SNPs by Sarah Briggs
Belgian case DNA extraction Hans Prenen
Belgian control DNA extraction Isabelle Cleynen
Belgian case genotyping Claire Palles
Belgian control genotyping Claire Palles
Dutch Extension case DNA 
extraction Auke Verhaar
Dutch Extension control DNA 
extraction Kausila Krishnadath
Dutch Extension case genotyping Claire Palles
Dutch Extension control genotyping Claire Palles
BEACON case/ control genotypes 
for the 7 SNPs selected for 
Replication Phase 3.
BEACON members Genotypes supplied by BEACON/BEAGESS
BE/EAC SNP analysis Claire Palles and Laura Chegwidden
Imputation Claire Palles
Functional Analysis Laura Chegwidden and Claire Palles
Association Testing and Meta-
analysis
Laura Chegwidden, Claire Palles 
and Xinzhong Li
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Table 7.2: Contributions of individuals at each stage of the Levine study replication. 
Section Researcher Comments
Levine SNP selection Laura Chegwidden, Claire Palles,  Ian Tomlinson, Janusz Jankowski
Imputation of all 87 Levine SNPs Claire Palles
Genotyping 4 SNPs selected from the 
remaining 83 Levine SNPs
Laura Chegwidden, Claire Palles, 
Claire Adams, John Findlay
Laura Chegwidden: genotyped 4 
SNPs in Replication Phases 1, 2 and 
3, genotyped 1 SNP in Discovery; 
Claire Palles: Aided genotyping when 
available; Claire Adams: Aided case 
DNA plating; John Findlay: Helped 
genotype 1 SNP
Principle component analysis Claire Palles
Association Testing and Meta-analysis Claire Palles, Laura Chegwidden, Xinzhong Li
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8. MATERIALS AND METHODS 
The research carried out for this degree is a replication study of the BE GWAS paper 
published by Su et al (2012) [2]. There is an overlap of samples used in UKREP2 and 
the Irish Replication. However, the SNP selection between the BE GWAS paper [2] 
and the replication study is different, due to increasing the P value threshold after 
combining data from Discovery, UKREP1 and the Dutch Replication sample sets 
(P<10-4 rather than P<10-8; described in section 8.4.1). 
In this section, a description of the cases and controls, genotyping methods, SNP 
selection, quality control and statistical methods used for the replication study will be 
provided. 
8.1 SAMPLE SETS 
Cases and controls used in each phase of the replication study are detailed below. An 
overview of the BE GWAS samples and the Replication study samples is provided in 
Table 8.1. All phases consist of unrelated individuals of white Caucasian origin and 
each sample set is independent of one another. 
8.1.1 Cases 
BE cases within the UK, Irish, Belgian and Dutch Replication Phases were acquired 
through the ChOPIN study and the EAGLE consortium [7].  
Patient recruitment to ChOPIN consisted of a baseline blood sample and completion of 
a Patient History Form (shown in the appendices: Figure 11.1), to record all phenotypic 
information (such as dysplasia and presence/absence of IM). All cases were initially 
diagnosed with BE by endoscopy, which was subsequently confirmed by histology. 
Individuals with BE lengths of ≥1cm (C1M1) circumferential disease or ≥2cm tongue 
patterns (C0M2), according to the Prague criteria [129] (Figure 8.1, from 
www.iwgco.net), were recruited to ChOPIN. Participants included in this research were 
unrelated and of white Caucasian origin. Presence of EAC in these patients
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(either at the time of recruitment or afterwards) was recorded but was not an 
inclusion/exclusion criterion. 
8.1.1.1 Replication Phase 2 cases 
UKREP 2 cases 
1,765 BE cases (71.4% male, 0.6% not stated) from NHS sites across the UK.  
Irish Replication cases 
245 BE cases (64.1% male, 8.6% not stated) from St. James’s Hospital and Mater 
Misericordiae University Hospital, Dublin. 
Figure 8.1: Prague Criteria. Figure designed by the International 
Working Group for the Classification of Oesophagitis (IWGCO). Figure 
from www.iwgco.net. 
48 
8.1.1.2 Replication Phase 3 cases 
UK Replication 3 (UKREP3) cases 
997 BE cases (70.9% male, 1.6% not stated) from NHS sites across the UK. 
Belgian Replication cases 
362 BE cases (66.0% male, 12.3% not stated) from Leuven, Belgium. 
Dutch Extension cases 
64 cases (28.1% male, 68.8% not stated) from Nijmegen and Rotterdam, Netherlands.  
BEACON cases 
A total of 3,295 BE cases (75.5% male), predominantly of Northern European descent, 
collected as part of the BEACON consortium GWAS (Chief Investigators: T Vaughan, 
D Whiteman, D Levine). 
8.1.2 Controls 
Control subjects were derived from various sources outlined below. 
8.1.2.1 Replication Phase 2 controls 
UKREP2 controls 
1,586 controls (45.2% male, 4.3% not stated) from the Colorectal Tumour Gene 
Identification (CoRGI) Consortium (Chief Investigator: I Tomlinson). This study aims to 
identify genes that increase the risk of bowel cancer or non-cancerous tumours (polyps 
and adenomas). The controls used in this study consisted of individuals unaffected by 
cancer and without a family history of colorectal neoplasia [127]. 
Irish Replication controls 
473 controls (35.1% male, 0.6% not stated) were provided by Trinity Biobank, Dublin. 
The Biobank, established in 2004, facilitates processing, storage and distribution of 
specimens for clinical and epidemiological research undertaken in Trinity College (St 
James’s Hospital). 
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8.1.2.2 Replication Phase 3 controls 
UKREP3 controls 
974 female controls from the Genetics of LobulAr Carcinoma In situ in EuRope 
(GLACIER) study (Chief Investigators: E Sawyer, R Roylance). GLACIER aims to 
identify genetic changes in patients with lobular carcinoma, in situ, of the breast to gain 
a greater depth of understanding of the disease and possible treatment options. The 
controls used in this study consist of individuals with no personal or family history of 
breast cancer [130]. 
Belgian Replication controls 
848 controls (47.6% male) from Leuven, Belgium. 
Dutch Extension controls 
206 controls (61.7% male) from Nijmegen and Rotterdam. 
BEACON controls 
3,204 controls (72.6% male), predominantly of Northern European descent, were 
provided by the BEACON consortium GWAS (BEAGESS). 
8.2 ETHICAL CONSIDERATIONS 
Written informed consent was obtained from all subjects. The ethics of the project were 
reviewed by the East London and the City Research Ethics Committee (04/Q0603/1). 
All UK studies were implemented with national ethics committee approval (MREC 
numbers: ChOPIN/IPOD 06/Q1603/07; CORGI 06/Q1702/99; and GLACIER 
06/Q1702/64). The Irish samples were collected with approval from the Research 
Ethics Committee Board of St. James’s Hospital. The Dutch extension and Belgian 
replication samples were collected with approval from the ethics committee or 
institutional review board of all participating institutions. The BEACON/BEAGESS 
project obtained informed consent from all recruited participants, and was approved by 
the ethics boards of each participating institution. 
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8.3 GENOTYPING 
8.3.1 DNA Extraction, Quantification and Concentration 
Genomic DNA (gDNA) for Replication Phase 2 (UKREP2 and Irish) cases and controls 
had been extracted and quantified previously for the published BE GWAS [2].  
Case and control gDNA for UKREP3 and the Dutch Extension were extracted using 
Maxwell® 16 Research Instrument (Promega UK) at the Wellcome Trust Centre for 
Human Genetics, Oxford (WTCHG). 
For UKREP3 samples, gDNA was quantified using the Nanodrop 2000 (Thermo Fisher 
Scientific Inc) UV-Vis Spectrophotometer. Concentrations recorded by the Nanodrop 
instrument were halved, to allow for over-estimation of gDNA content. Samples with a 
concentration of >20ng/µl and an A260/280 score of 1.5-2.5 were deemed sufficient for 
genotyping (N=302). Samples with a concentration <20ng/µl or with an A260/280 score 
of <1.5 or >2.5 were concentrated using SPD2010 Integrated SpeedVac™ Systems 
(Thermo Fisher Scientific Inc) and re-suspended in molecular grade water to produce a 
concentration of 20ng/µl (N=308). Nanodrop readings were re-taken for the 308 gDNAs, 
samples which still failed to meet the criteria were re-extracted (N=16). 
Belgian case and control gDNAs were extracted and quantified by Hans Prenen and 
Isabelle Cleynen, respectively, in Belgium. 
Dutch Extension case and control gDNAs were extracted and quantified by Auke 
Verhaar and Kausilia Krishnadath respectively, in the Netherlands. 
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8.3.2 Genotyping Methods used 
8.3.2.1 Sequenom iPLEX® MassArray® 
Three custom Sequenom iPLEX® MassArray® platforms were designed by Dr Claire 
Palles and genotyped at the WTSI. The assay consists of multiple steps [131]. First, 
the gDNA undergoes a locus-specific PCR reaction. Secondly, all unincoporated 
dNTPs are removed using shrimp alkaline phosphatase (SAP), which cleaves a 
phosphate from the unincorporated dNTPs, converting them to dNDPs and rendering 
them unavailable to future reaction. This is then followed by the iPLEX reaction, where 
there is locus-specific extension of the annealed primer upstream of the target SNP. 
During the iPLEX reaction, the primer and DNA are incubated with mass-modified 
dideoxynucleotide terminators [4, 131]. The dideoxynucleotides will have differing 
mass, dependent on the base incorporated, which can be assessed using Matrix 
Assisted Laser Desorption/Ionization-Time of Flight (MALDI-TOF) mass spectrometry. 
This mass difference allows the data analysis software to differentiate between SNP 
alleles [132]. Genotypes were assigned using MassArray® Analyzer 4 System® [132]. 
An overview of the Sequenom iPLEX® MassArray® workflow is outlined in Figure 8.2 
(adapted from Gabriel et al (2009) [4]). 
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Figure 8.2: Sequenom iPLEX MassArray Workflow. Adapted from Gabriel et al (2009) [4]. 
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8.3.2.2 Illumina® HumanHap550 
The Illumina® HumanHap550 BeadChip (Illumina Hap550) contains probes for 550,352 
SNPs (www.illumina.com) and utilises the Infinium® HD Assay [133]. For each SNP, 
specific 50-mer oligonucleotide probes (oligos) are covalently linked to beads, which 
are then dispersed into the wells. The Infinium® HD Assay was designed to provide 
high-quality, accurate results quickly. Firstly, gDNA samples are denatured and then 
isothermally amplified (no PCR is needed). The amplified gDNA is then fragmented by 
a controlled enzymatic step, producing a target gDNA fragment size of around 300bp. 
After an isopropanol precipitation, the fragmented gDNA is collected by centrifugation 
and then re-suspended in hybridization buffer. Samples are then loaded onto the 
BeadChip and incubated. The gDNA will anneal to the specific oligos present on the 
beads. gDNA which is either unhybridized or non-specifically hybridized after the 
previous annealing step is then washed away. Detectable labels are then incorporated 
on the BeadChip by Single-base extension (SBE) of the oligos, which determines the 
genotype call. The BeadChip is then scanned, using a laser to excite the fluorophore 
attached to the SBE product on the beads, and records images of the emitted light 
[133-136]. An overview of the workflow can be seen in Figure 8.3. 
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Figure 8.3: Overview of the Illumina® Infinium® HD Assay workflow  Figure 8.3: Overview of the Illumina Infinium HD Assay Workflow 
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8.3.2.3 Illumina® Immunochip® 
The Immunochip®, initiated by the WTCCC, is an Illumina® Infinium® iSelect HD custom 
genotyping array, designed by the Immunochip Consortium. The chip contains 196,524 
polymorphisms, located in regions of the genome that show evidence of association to 
immune-mediated diseases, including BE. It is designed for use in white European 
populations and is a relatively low-cost option compared to other GWAS chips [137]. 
The Illumina Infinium HD assay is described in the section above (8.3.2.2) and an 
overview of the workflow can be seen in Figure 8.3. 
8.3.2.4 KASPar 
KASPar is a homogeneous, endpoint PCR genotyping technology. The KASPTM assay 
relies on Fluorescence Resonance Energy Transfer (FRET) to distinguish between 
SNP alleles. The allele-specific primers each have a sequence that corresponds to one 
of two FRET cassettes (one labelled with FAMTM dye and one with HEXTM dye) on the 
5’ end. Allele discrimination is achieved through the competitive binding of the two 
allele-specific primers [138, 139]. 
The KASP genotyping reaction is made up of three elements; gDNA, assay mix and 
master mix. The assay mix for this technology consists of two allele-specific primers 
and one common primer. Primers were ordered desalted on the 0.025M scale and are 
listed in Table 11.2. The primers were made up to a concentration of 0.1nmol/µL.  
Firstly, 1mL of assay mix was prepared consisting of 12µL the Allele 1 primer, 12µL of 
the Allele 2 primer, 30µL of the common primer and 46µL of molecular grade water. 
The concentrations in the prepared 1mL of assay mix were as follows: 0.012nmol/µL of 
allele 1 primer, 0.012nmol/µL of allele 2 primer and 0.030nmol/µL of the common 
primer. The master mix was then prepared; each well (reaction) required 5µL KASPar 
2X reaction buffer, 0.14µL of the previously prepared assay mix and 3.86µL of 
molecular grade water. The primer concentrations per reaction were as follows: 
0.114nmol/µL of allele 1 primer, 0.114nmol/µL of allele 2 primer and 0.286nmol/µL of 
the common primer.  
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The 2X KASPar Reaction buffer contained the FAM and HEX specific dyes, passive 
reference dye ROX, modified Taq polymerase for allele-specific PCR and buffer [139, 
140]. The master mix was prepared in batches (enough for at least one plate at a time) 
on the day of use. An overview of the assay mixes can be found in Table 8.2.  
To each well, of the ABI Fast Taqman plates, the following were added: 1.5µL of 
20ng/µL gDNA (the minimum recommended volume and concentration of gDNA) and 
9µL of the prepared Master mix (recommended minimum total aliquot per well is 10µL 
due to evaporation, according to LGC Genomics [140]). The plates were then sealed 
with ABI optical plate seals and pulse-centrifuged for 10 seconds.  
The sealed plates were placed on the G-STORMTM GS4 Multi Block Thermal Cycler, 
with heat mats to prevent excess evaporation. The gDNA then underwent a 3-step 
KASPar PCR reaction. The first step was activation at 94°C for 15 minutes. The 
second step was 10 cycles of denaturation at 94°C for 20 seconds and 
annealing/elongation at a 61°C-55°C temperature titration for 1 minute, dropping 0.6°C 
per cycle. The final step consisted of 26 cycles of denaturation at 94°C for 20 seconds 
and annealing/elongation at 55°C for 1 minute [140]. An overview of the PCR reaction 
can be found in Table 8.3.  
 
Table 8.2: KASP Assay and Master mixes. Primers 
must be made up to 100µM. Assay mix detailed 
above makes 1ml, enough for roughly 7 96-well 
plates. Master mix above shows the amount needed 
per well, to be added to the 2µL of DNA in each well. 
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All plates were removed from the thermocycler at the end of the program and pulse-
centrifuged for 10 seconds. The plates were then read on Applied BiosystemsTM 
7900HT Fast Real-Time PCR System using SDS software 2.4 (Applied BiosystemsTM). 
Plates where the genotypes were not adequately clustered were subjected to 10 extra 
cycles, under the temperatures seen in Step 3 of Table 8.3 [140].  
An overview of the KASP genotyping technology is available in Figure 8.4. 
 
Step Description Temp (°C) Time N Cycles
1 Activation 94 15 mins 1
Denature 94 20 ses
60 secs
(drop 0.6°C per cycle)
Denature 94 20 ses
Annealing/ Elongation 55 60 secs
2 10
Annealing/ Elongation 61-55
3 26
Table 8.3: KASPar Genotyping PCR details 
PCR$1:$DNA$denatured$and$primers$annealed$
Allele$1:$FAM$
A$
T$
5’$3’$
3’$
5’$
Reverse$primer$
PCR$2:$Elonga>on$of$primers$and$genera>on$of$the$
complement$speciﬁc$tail$sequence$and$signal$
A$
T$
5’$
3’$
Allele$2:$HEX$
5’$ 3’$
Allele$2$does$not$bind$in$
this$case.$It$remains$
quenched$in$the$KASP$
Master$Mix,$and$therefore$
no$HEX$signal$is$produced.$
PCR$3:$Signal$intensity$increases$with$each$round$of$PCR$
A$
T$
5’$
3’$
Plate$Reading$and$Genotype$Calling$
TT$
AT$
AA$
Figure 8.4: KASP genotyping Technology  Figure 8.4: KASP Genotyping Technology 
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In detail, the first round of PCR entails DNA denaturation, common primer hybridization 
and elongation, and allele-specific primer (specific to the SNP in the assay) 
hybridization and elongation (with a 5’ tail). During the second PCR reaction (“PCR 2” 
in Figure 8.4), the common primer binds to the template and extends. This produces a 
complementary sequence to the 5’ tail created in “PCR 1”. This then allows the oligos 
with the attached fluorophore (specific to the SNP) to hybridize. Upon hybridization the 
fluorophore is released from its quencher. This process continues (fluorophore 
hybridization and quencher release) during the amplification of the PCR product in 
order to obtain a strong signal [141]. 
Before genotyping all gDNAs, each SNP was subjected to an optimisation step. Two 
common primers were ordered and genotyped on one plate (half with common primer 
1 and half with common primer 2). Using Applied BiosystemsTM 7900HT Fast Real-
Time PCR System and SDS software 2.4 (Applied BiosystemsTM), each half of the 
plate was visualised and the primer that gained tighter clustering was selected for 
genotyping all gDNA. An example of the optimisation step can be seen in Figure 8.5.  
8.3.2.5 Illumina Omni 1M 
The Illumina Omni 1M platform covers over 1 million SNPs across the genome and 
uses the Illumina Infinium HD assay as described in section 8.3.2.2 and seen in Figure 
8.3. 
All BEACON cases and controls were genotyped on the Illumina Omni 1M and 
genotypes were provided by the consortium.  
8.3.3 Quality Control 
8.3.3.1 Sequenom 
Any gender discrepancies between samples or SNP call rates of <95% were excluded 
from the analysis.  
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8.3.3.2 KASPar 
The 7 SNPs genotyped by KASPar in Replication Phase 3 had call rates >95%. 
Samples were excluded if there were any gender discrepancies and SNPs were 
excluded if call rates were <95%. At least two negative controls were included on each 
plate and a positive control was used when validating each SNP and when SNPs had a 
low allele frequency. Genotyping quality control (QC) was tested for samples analysed 
solely by KASPar using duplicate DNA samples within studies and SNP assays. For all 
SNPs, >98% concordant results were obtained.  
Figure 8.5: Optimisation of primers used for KASP genotyping. Showing 
common primer 1 (A) and common primer 2 (B). Common Primer 2 was 
selected in the case illustrated due to tighter clustering of the heterozygotes 
and high auto-call rates. 
A: 
B: 
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8.4 REPLICATION STUDY SNP SELECTION 
8.4.1 Replication Phase 2 SNPs 
Although the Replication Phase 2 samples have been used previously in the original 
BE GWAS [2], the SNP selection criteria were relaxed for the replication study. In the 
BE GWAS only two SNPs were genotyped by KASPar. In this replication study, 83 
SNPs were selected for genotyping on Sequenom iPLEX® MassArray® provided they 
met one of the four criteria below, based on data (Discovery and/or Replication Phase 
1) from the previous BE GWAS [2] or on candidate SNPs [46, 110]. 
(i) P value <10−4 in combined Discovery and Replication Phase 1 analysis 
(N=63) from the previous BE GWAS [2] 
(ii) P value <10−4 in Discovery Phase, but not included in Replication Phase 
1 (N=12) published by Su et al (2012) [2] 
(iii) P value <10−4 in a sex-stratified analysis of the Discovery phase (N=5) in 
Su et al (2012) [2] 
(iv) Candidate polymorphisms previously reported as associated with BE 
and not well tagged by the Discovery Phase or Replication Phase 1, 
specifically, MSR1 p.Arg293Gly [46], and variants in IGF1R and GHR 
[110] (N=3). 
Sequenom iPLEX assays (as described in section 8.3.2.1) were successfully designed 
for 65 of the SNPs outlined above (Table 11.1). Any SNP in the top 40, ranked by P 
value, which failed during the design stage of the Sequenom iPLEX, was genotyped by 
KASPar (N=3). Unfortunately, 18 SNPs on the iPLEX design could not be analysed in 
the Irish replication set, as they were not present on the Immunochip (described in 
section 8.3.2.3). 
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8.4.2 Replication Phase 3 SNPs 
SNPs selected for genotyping in Replication Phase 3 samples were based on a meta-
analysis between Discovery set and Replication Phase 1 samples published in Su et al 
(2012) [2] with Replication Phase 2 samples above (section 8.4.1).  
After meta-analysis, SNPs were selected for further investigation using an arbitrary cut 
off of P<5x10-6. Firstly, the Linkage Disequilibrium (LD) data was assessed for all SNPs 
using the SNP Annotation and Proxy Search (SNAP) database 
(www.broadinstitute.org/mpg/snap/). If a SNP was found to be in LD (r2>0.4) with 
another, then the SNP with the more significant P value was selected for genotyping at 
that locus. One SNP with P<5x10-6, rs9936833, was not genotyped further in 
Replication Phase 3 samples, as this was a SNP previously reported by Su et al (2012) 
[2] in the initial BE GWAS. The remaining independent SNPs were selected for further 
replication in all Replication Phase 3 samples. 
8.4.3 Replication Phase 3 Power Calculations 
Power calculations for the Replication Phase 3 SNPs were determined using an in 
house power calculation tool developed by Doug Altman. The most frequently used 
test in genotype-based analysis for case-control genetic association studies is the 
Cochran-Armitage Trend test; this was therefore used in this study.  
Calculations were performed for all seven Replication Phase 3 SNPs in UKREP3 (997 
cases and 974 controls) and all Phase 3 replication samples (UKREP3, Belgian, Dutch 
Extension and BEACON; 4697 cases and 5205 controls). 
8.5 STATISTICAL METHODS 
8.5.1 PLINK 
PLINK [142] (http://pngu.mgh.harvard.edu/~purcell/plink/) was used to check the 
frequency of each SNP to determine the major/minor allele. To use PLINK, a MAP and 
PED file were created as detailed below. Note that the columns in the PED file must 
match the rows in the MAP file.  
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8.5.1.1 MAP File 
The MAP file contains 4 columns, with one SNP per line: 
(i) Chromosome number 
(ii) rs number 
(iii) Genetic distance (morgans) 
(iv) Base-pair position 
An example of three SNPs can be found in Figure 8.6A. 
8.5.1.2 PED File 
A PED file is a space or tab delimited file. The first six columns are always as follows: 
(i) Family ID 
(ii) Individual ID 
(iii) Paternal ID 
(iv) Maternal ID 
(v) Sex (1=male; 2=female; other=unknown) 
ChP102734 ChP102734 0 0 1 1 CT TT GG
ChP103800 ChP103800 0 0 2 1 CT TT AA
ChP104244 ChP104244 0 0 1 1 CC GT AG
ChP101440 ChP101440 0 0 1 1 CT GT GG
15 rs189247 0 95387634
16 rs2043633 0 5759275
12 rs2701108 0 113158644
A: 
B: 
Figure 8.6: Files required for PLINK. MAP file example (A) for three SNPs. 
Columns as follows: chromosome number, rs number, Genetic distance 
(morgans), Base-pair position (bp units). PED file example (B) for four cases 
in three SNPs. Columns as follows: Family ID, Individual ID, Paternal ID 
(0=missing), Maternal ID (0=missing), Sex (1=male, 2=female), Phenotype 
(1=case, 0=control), Genotype for rs189247, Genotype for rs2043633, 
Genotype for rs2701108. NB. The columns in the PED file must match the 
rows in the MAP file. 
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(vi) Phenotype 
 
Genotypes are noted in column 7 onwards. An example of a PED file can be found in 
Figure 8.6B. In this study, the Family and Individual ID are the same and neither 
Paternal nor Maternal IDs were given. 
8.5.1.3 PLINK command line 
An example of the PLINK command line used in this study is shown below in italics. 
The following parameters were used in this research: 
--file <fileroot>: specify the root filename of the PED and MAP files to be used. 
--freq: output the allele frequencies. 
--compound-genotypes: use AA, AG, 00 coding (no spaces between alleles in the PED 
file). 
--out: specify output root filename 
Specifically: plink --file UKREP3_snps --freq --compound-genotypes --out 
/Laura/freq_BO 
8.5.2 GTOOL 
GTOOL was employed to convert the MAP and PED files to GENOTYPE (GEN) and 
SAMPLE files, needed for SNPTEST. Firstly all missing data, denoted by -9’s for the 
MAP and PED files, were replaced with NA’s before using GTOOL. 
8.5.2.1 GENOTYPE File 
The GEN file stores data on each specific SNP on one line (one SNP per line). The first 
5 columns are as follows: 
(i) SNP ID  
(ii) rs number 
(iii) Base-pair position of the SNP 
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(iv) Allele A  
(v) Allele B 
The SNP ID was used for chromosome number in this study.  
An example of the GEN file for one SNP in two cases can be seen in Figure 8.7A. The 
three numbers in columns 6, 7 and 8 show the probabilities of the three genotypes (AA, 
AB and BB) for the first case. The next set of three numbers show the genotype 
probabilities for the second case. This repeats for all cases in the GEN file. 
8.5.2.2 SAMPLE File 
The first three columns on the SAMPLE file are as follows:  
(i) ID_1 
(ii) ID_2 
(iii) Missing 
Each case has two ID’s (columns 1 and 2) and missing data proportion (column 3). 
Additional entries used in this study were sex (however, this data was not analysed) 
and case. An example of the SAMPLE file can be found in Figure 8.7B. 
 
16 rs2043633 5759275 G T 0 1 0 0 1 0
0 0 0 D B
ChP102227 ChP102227 0.076923 NA 1
ChP102572 ChP102572 0.384615 NA 1
A: 
B: 
Figure 8.7: Files created using GTOOL. GEN file example (A) for one SNP in two cases. The first five 
columns are: Chromosome number, RS number, Base-pair position of the SNP, Allele A, Allele B. The 
first set of three numbers show the probabilities of the three genotypes (AA, AB and BB) for the first 
case, the second set of three numbers show the probabilities for the second case. SAMPLE file example 
(B). Columns are as follows: ID_1, ID_2, missing, sex, case. Each individual can have two IDs (only one 
was used in this study). Sex was not included in the analyses, hence NA. The first line defines the type 
of variables used in each column; 0=no variable, D= Discrete, B= Binary Phenotype (eg. 0 = Controls, 1 
= Cases). Both the GEN and SAMPLE file are tab-delimited files. 
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8.5.2.3 GTOOL command line 
An example of the GTOOL command line used can be seen in italics below. The 
following parameters were used: 
-P: PED to GEN conversion mode  
--ped <filename>: specify PED format genotype file 
--map <filename>: specify the MAP SNP file which accompanies the --ped file 
--binary_phenotype: the phenotype in the output sample file is 'B'. 
--og: output genotype file. Default, append .gen to PED file name. 
--os: output sample file. Default, append .sample to PED file name. 
Specifically:   
gtool -P --ped UKREP3 _cases.ped --map UKREP3_ cases.map --binary_phenotype --
og UKREP3_ cases.gen --os UKREP3_ cases.sample 
8.5.3 Association Analysis using SNPTEST 
Case-control analysis was performed using frequentist tests under a missing data 
logistic regression model using SNPTEST (v2.4.1).  
8.5.3.1 Input Files 
The input files for SNPTEST are the GEN and SAMPLE files generated using GTOOL 
(Section 8.5.2).  
8.5.3.2 Output Files 
The output file contains the following information: rs number; chromosome number; 
base-pair position; allele A; allele B; Effect Allele (EA); the number of cases with AA, 
AB or BB genotype; number of cases with missing genotype; total case number; 
number of controls with genotypes AA, AB or BB; controls with missing genotype; total 
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control number; Minor Allele Frequency (MAF) of all samples; cases MAF; controls 
MAF; missing data proportion; case HWE; control HWE; heterozygous OR; 
heterozygous OR lower; heterozygous OR upper; homozygous OR; homozygous OR 
lower; homozygous OR upper; OR of all samples; OR lower of all samples; OR upper 
of all samples; P-value; BETA; SE (Standard Error). 
8.5.3.3 SNPTEST command line 
An example of the command line is shown below in italics. The parameters used were 
as follows: 
-hwe: calculate Hardy-Weinberg statistics for each cohort and combined data. 
-data <a> <b>: specify data files for analysis in GEN and SAMPLE pairs (for cases and 
controls). 
-o <a>: specify name of output file. 
-frequentist <a>: specify which Frequentist tests to fit. 
-method <a>: specify method used to fit model. 
-pheno <a>: specify name of phenotype to use. 
Specifically:  
snptest2 -hwe -data UKREP3.v3.gen UKREP3.v3.sample glacier_controls.v2.gen 
glacier_controls.v2.sample -o /Laura/UKREP3 -frequentist 1 -method score -pheno 
case 
The ‘-frequentist 1’ option was used to denote an additive model. The ‘-method’ option 
controls the way genotype uncertainty is taken into account when carrying out 
association tests. In this case, the ‘score’ option uses a missing data likelihood score 
test. The ‘-pheno’ option specifies which phenotype to test. In this study ‘case’ was 
used (to match the SAMPLE file). 
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Note that SNPTEST codes allele B as the EA, to which the BETA's and SE's are based 
on. This needs to be recalled when analyzing SNP effects. 
8.5.4 Meta-analysis using GWAMA 
Meta-analysis is used to combine results from various studies and/or sample sets, 
increasing the statistical power to identify significant variations within a given 
population. Combined analysis of the data outlined in this replication study relied upon 
sample sets used in the BE GWAS paper (consisting of the Discovery Phase, UKREP1 
and Dutch Replication) [2].  
GWAMA (v2.1) is a software tool for meta-analysis of whole genome association data. 
It was used in this study to implement fixed inverse variance-based methods for meta-
analysis [143].  
8.5.4.1 Input File 
The input file for GWAMA is required to have at least the following six columns for 
quantitative trait analysis: 
(i) rs number 
(ii) EA 
(iii) Non Effect Allele (NEA) 
(iv) P-value 
(v) BETA 
(vi) SE  
8.5.4.2 Output File 
GWAMA provides three output files. The first output file (gwama.out) contains the 
results and consists of the following columns: rs number; reference allele; other allele; 
Effect Allele Frequency (EAF); beta; SE; beta_95L (Lower 95% Confidence Interval (CI) 
for BETA); beta_95U (Upper 95% CI for BETA); z score; p-value; -log10 p-value; q 
statistic (Cochran's heterogeneity statistic); q p-value (Cochran's heterogeneity 
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statistic's p-value); i2 (Heterogeneity index i2); number of studies; number of samples; 
summary of effects direction.  
The second output file (gwama.log.out) contains the log information about the current 
GWAMA run. Each error and warning has unique error code. More information for them 
can be found in the gwama.err.out file.  
The gwama.err.out file is the third file produced by GWAMA and contains all errors and 
warnings generated during the GWAMA run.  
8.5.4.3 GWAMA command line 
An example of the GWAMA command line is shown below in italics. The parameters 
used were as follows: 
--filelist <filename>: specify studies' result files. For ease, a text file containing the path 
directories to each input file (one file per cohort) was created for use here. 
--quantitative or -qt: select quantitative trait version (BETA and SE columns). 
--output <fileroot>: specify file root for output of analysis. 
Specifically: 
gwama --filelist Discovery_RepPhase1_RepPhase2_RepPhase3.txt -qt --output 
/Laura/Meta_all 
8.6 IMPUTATION  
Imputation describes the process of predicting genotypes that have not been directly 
typed in a sample of individuals. It provides a high-resolution view of a region within the 
genome and increases the chance that a causal SNP can be directly identified. 
Imputed SNPs that show greater statistical significance compared to genotyped SNPs 
can be better candidates for replication studies [144].  
In this study, Dr Claire Palles used IMPUTE2 [145] 
(https://mathgen.stats.ox.ac.uk/impute/impute_v2.html) to impute 1Mb surrounding the 
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lead genotyped SNPs on chromosome (chr) 2p24.1 and chr12q24.21 in the Discovery 
data. The HapMap3 release 2 and the 2009 release of the 1000 genomes project were 
used as reference panels and recommended software parameters were applied.  
Hit plots of the two regions were created by Dr Claire Palles using Locus Zoom, LD 
information used was from the 2009 release of the 1000 genomes project, CEU 
samples.  
8.7 IN SILICO FUNCTIONAL ANALYSES 
In silico functional analysis allows scientists to predict the effect of disease-associated 
SNPs. These analyses are particularly useful for intergenic and intronic SNPs, where 
there is no obvious functional effect. 
The two new significant SNPs (rs3072 and rs2701108) were analysed using the 
following browsers: HaploReg V2 [146], Regulome DB [147], SNP and Copy number 
ANnotation (SCAN) [148], and ANNOVAR [149].  
8.7.1 HaploReg 
HaploReg [146] (http://www.broadinstitute.org/mammals/haploreg/haploreg.php) is an 
Encyclopedia of DNA Elements project (ENCODE)-funded tool that can be used for 
investigating possible regulatory SNPs at disease-associated loci. It was designed for 
scientists to aid the development of hypotheses on non-coding variants. Information on 
various SNPs such as chromatin state, sequence conservation, and their effect on 
regulatory motifs can be predicted based on LD information from the 1000 Genomes 
Project. This information could, in theory, provide helpful information on clinical 
phenotypes [146]. The parameters were set up as follows: r2 threshold of >0.4, 1000G 
Phase 1 LD calculation for European population, ENCODE was used for the 
epigenome source, Conservation algorithm included both Genomic Evolutionary Rate 
Profiling (GERP) and SiPhy-omega and SNP position was shown relative to RefSeq 
genes.  
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8.7.2 RegulomeDB 
RegulomeDB [147] (http://www.regulomedb.org/) is an ENCODE-funded database that 
annotates SNPs with known and predicted regulatory elements within introns. The 
database covers DNAase hypersensitivity, transcription factor binding sites, and 
promoters. The data present in the database comes from the Gene Expression 
Omnibus (GEO), ENCODE project, and published literature.  
The list of SNPs in LD with each of the new BE-associated SNPs with r2>0.4, produced 
by HaploReg, was entered on the RegulomeDB website. The results were then 
downloaded. 
8.7.3 SCAN 
SCAN [148] (http://www.scandb.org/newinterface/about.html) produces physical 
(location, flanking genes) and functional expression Quantitative Trait Loci (eQTL) 
annotation of SNPs. Information on physical, functional, and LD annotation on the 
database comes from public resources (HapMap (release 23a) and National Center for 
Biotechnology Information Single Nucleotide Polymorphism Database (NCBI dbSNP).  
Each SNP list (the BE-associated SNP and those in LD, with r2>0.4) was entered on 
the SCAN website. All default options were selected for analysis (include SNP info, 
include host gene and SNP function, include left- and right- flanking genes, include 
genes that SNP predicts expression for with P value less than 0.0001). 
8.7.4 ANNOVAR 
ANNOVAR [149] (http://www.openbioinformatics.org/annovar/) is a software tool which 
uses up to date information to functionally annotate genetic variants in a variety of 
genomes. This tool was used to perform gene-based annotations, region-based 
annotations and filter-based annotations. The annotations selected for the two 
genome-wide significant SNPs were refGene (gene-based), GERP (filter-based), 
PhastCons (region-based) and SiPhy (filter-based). RefGene was used to provide the 
location of each SNP and it’s distance from nearby Refseq genes. The GERP 
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annotation was used to provide a GERP score of conservation, which ranges from -
12.3 to 6.17, with 6.17 being the most conserved. The PhastCons annotation was used 
to assess conservation of genomic regions. PhastCons scores range from 0-1000, with 
1000 being the most conserved. Finally, the SiPhy annotation was employed to assess 
conservation across 29 mammalian genomes; the larger the score, the more 
conserved the site. 
8.7.4.1 Input File 
An input file for each SNP list (the BE-associated SNP and those in LD, with r2>0.4) 
was produced for ANNOVAR. Each tab-delimited input file (.avinput) required the 
following columns: 
(i) Chromosome 
(ii) Start position 
(iii) End position 
(iv) Reference nucleotide 
(v) Observed nucleotide 
8.7.4.2 Files Downloaded for Analysis 
In order to annotate each SNP list with the gene-, region- and filter-based annotations 
listed above, four files from the ANNOVAR website were downloaded as follows, note 
that the files used were in relation to hg19: 
(i) hg19_refGene.txt: FASTA sequences for all annotated transcripts in RefSeq 
Gene 
(ii) hg19_gerp++gt2.txt: whole-genome GERP++ scores greater than 2 (RS score 
threshold of 2 provides high sensitivity while still strongly enriching for truly 
constrained sites). 
(iii) hg19_phastConsElements46way: PhastCons Scores 
(iv) hg19_ ljb23_siphy: whole-exome SiPhy scores (version 2.3).  
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An example of the command line used to download the GERP++ file, using a perl script, 
from ANNOVAR can be seen below in italics. ‘-downdb’ denotes download database, ‘-
buildver <version>’ specify which build version to download (hg19 in this case), ‘-
webfrom <source> <file> <output location>’ specify the download source, file to 
download and output location of that file. 
perl annotate_variation.pl -downdb -buildver hg19 -webfrom annovar gerp++gt2 
humandb/ 
8.7.4.3 Analysis 
Due to the presence of more than one annotation, the table_annovar perl script was 
employed for analysis. This allows a one-line command to produce multiple 
annotations per input file and output a comma-separated value file. The .csv file can be 
viewed in excel, where each annotation is shown in a separate column. The 
parameters used were as follows: 
table_annovar.pl <input file>: defines which perl script to use and location and name of 
input file 
humandb/: defines the location of the protocol files (refGene, PhastCons, GERP and 
SiPhy) 
-buildver <version>: specify the build version 
-out <filename>: specify the output file name 
-remove: denotes removal of all temporary files produced before configuring the .csv 
output file 
-protocol <a,b,c,d>: specify the annotation protocol files to use 
-operation<a,b,c>: specify the operation of the protocols used (g=gene-based, 
r=region-based, f=filter-based) 
-nastring <a>: specify what to insert in the output file if the annotation is empty 
-csvout: denotes the csv output file. 
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Specifically: 
perl table_annovar.pl example/rs2701108.avinput humandb/ -buildver hg19 -out 
rs2701108 -remove -protocol 
refGene,phastConsElements46way,gerp++gt2,ljb23_siphy -operation g,r,f,f -nastring 
NA –csvout 
8.7.4.4 Output File 
The output file consisted of the following columns: 
(i) Chromosome 
(ii) Start postition 
(iii) End postition 
(iv) Reference Allele 
(v) Alternative Allele 
(vi) Function according to refGene 
(vii) Nearby Genes according to refGene 
(viii) Gene Detail (distance of SNP from gene) from refGene 
(ix) Exonic Function according to refGene 
(x) Amino acid change according to refGene 
(xi) PhastCons score according to phastConsElements46way 
(xii) GERP score according to gerp++gt2 
(xiii) SiPhy score according to ljb23_siphy 
An example of the output file in excel is shown in Table 8.4, showing the first three 
Chr Start End Ref Alt Func.refGene Gene.refGene GeneDetail.6
refGene
ExonicFunc.6
refGene
AAChange.
refGene
phastConsEle
ments46way
gerp++gt2 ljb23_siphy
12 114660658 114660658 T C intergenic RBM19,TBX5
dist=256482;
dist=131077 NA NA
Score=556;A
Name=A
lod=243
NA NA
12 114661066 114661066 C G intergenic RBM19,TBX5 dist=256890;
dist=130669
NA NA NA 2.1 NA
12 114661789 114661789 A T intergenic RBM19,TBX5 dist=257613;
dist=129946
NA NA NA NA NA
Table 8.4: Example of the ANNOVAR functional analysis, showing the output file for the first three SNPs of the rs2701108 analysis, in Microsoft 
Excel. ANNOVAR was used to annotate SNPs in LD (r2>0.4) with the new BE-associated SNPs. The ANNOVAR table_annovar perl script was used with the 
following protocols, downloaded from the ANNOVAR website, for SNP annotation: hg19_refGene.txt, hg19_gerp++gt2.txt, hg19_phastConsElements46way.txt 
and ljb2_siphy.txt. 
able 8.4: Example of the ANNOVAR functional analys s, showing the output file for the first three 
SNPs of the rs2701108 analysis, in Microsoft Excel. ANNOVAR was used to annotate SNPs in LD 
(r2>0.4) with the new BE-associated SNPs. The ANNOVAR table_annovar perl script was used with the 
following protocols, downloaded from the ANNOVAR website, for SNP annotation: hg19_refGene.txt, 
hg19_gerp++gt2.txt, hg19_phastConsElements46way.txt and ljb2_siphy.txt. 
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SNPs of the rs2701108 input file analysis. 
8.8 ASSOCIATION TESTING OF THE FOUR BE SNPS IN EAC CASES 
BE predisposes patients to EAC. It was therefore decided to explore the link between 
the two diseases. 
8.8.1 Adenocarcinoma Case Selection 
Case phenotypes reported as Siewert type 1 adenocarcinomas without any evidence 
of BE (therefore EAC-only) were used in this section of the study. Siewert type 2 or 3 
adenocarcinomas were not used due to the close proximity to the stomach, and hence 
possible misdiagnosis of stomach cancer. 
8.8.2 Sample Set 
An independent set of 305 UK and 176 Dutch cases (481 in total) were used. These 
samples were collected as part of ChOPIN.  
The controls used in this stage were the same as those used in Replication Phase 1 of 
the BE analysis (UK N=6,819 from PoBI and 58C; Dutch N=1,780 from University 
Medical Centre, Groningen). 
8.8.3 Genotyping 
All gDNA had been extracted previously under the BE GWAS, but had not been 
analysed. The genotypes for the selected SNPs, detailed below, were extracted from 
the Immunochip. 
8.8.4 SNP Selection 
Four SNPs associated with BE (the two previously identified SNPs: rs9257809 and 
rs9936833; and the two newly identified SNPs: rs3072 and rs2701108) were selected 
for analysis. 
8.8.5 Analysis 
Association testing was performed for a case-control analysis using the EAC-only 
cases and Replication Phase 1 controls. In addition to this, a case-only meta-analysis, 
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using BE cases from Replication Phase 1 and the EAC-only cases outlined here, was 
performed consisting of; UK 2,957 BE vs 305 EAC-only and Dutch 473 BE vs 176 
EAC-only.  
8.9 REPLICATION OF BE/EAC SNPS REPORTED BY LEVINE ET AL (2013) 
[3] 
A combined BE/EAC GWAS paper was published by Levine et al (2013) [3] (comprising 
2,363 EAC cases, 3,116 BE cases and 10,060 controls) whilst completing this replication 
study [3]. The paper analysed 922,031 SNPs in the Discovery phase and 87 of 94 SNPs 
with P<1×10−4 in the replication phase. Levine et al (2013) [3] identified four SNPs (three 
loci) associated with BE/EAC risk: rs2687201, rs11789015, rs10419226, and 
rs10423674.  
8.9.1 Controls 
The controls for each sample set was the same as in the BE analysis apart from the 
Discovery phase controls. The WTCCC2 controls used in our original Discovery phase 
overlapped with those in Levine et al (2013) [3], hence new controls from colorectal 
cancer GWAS studies CORGI and Colon Cancer Family Registry (CFR) were used 
[127, 150]. The details of CORGI are available in section 8.1.2. The CRF cohort is an 
international consortium of six institutes in North America and Australia, which provides 
support to studies on the etiology, prevention, and clinical management of colorectal 
cancer. The cohort comprises data and specimens from over 40,000 participants from 
14,000 families that have been recruited from 1998 to 2011 [150]. 
8.9.2 Replication Analysis of the four BE/EAC-associated SNPs 
8.9.2.1 Cases 
The cases included in this replication study varied depending on the SNP analysed.  
Three of the four SNPs (rs2687201, rs11789015 and rs10419226) were not directly 
genotyped in our samples. Therefore, they were imputed (see section 8.9.4) in only our 
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Discovery phase, resulting in SNP association testing in 3 sample sets overall: the 
Levine Discovery, Levine Replication and our Discovery.  
However, rs10423674 was directly genotyped in our Discovery, UKREP1 and Dutch 
replication samples, and so was analysed in 5 sample sets overall: the Levine 
Discovery, Levine Replication, Our Discovery, UKREP1 and Dutch Replication. 
8.9.3 Replication Analysis of the remaining 83 SNPs 
8.9.3.1 SNP selection 
From the 87 BE/EAC SNPs from Levine et al (2013) [3], 83 were yet to be analysed in 
our data. Only 10 of these 83 were not genotyped or reliably imputed (see section 8.9.4) 
with an info score >0.95. One of the 10 SNPs, rs11771429, had P<10-5, consequently, 
this SNP was genotyped using the KASP genotyping technology (section 8.3.2.4) in 
our Discovery phase samples. Therefore, 74 SNPs were included in the meta-analysis 
of Levine’s Discovery, Levine’s Replication and our Discovery. Four SNPs were 
selected for further replication based on P value and LD information: rs1497205, 
rs254348, rs3784262 and rs4523255. 
8.9.3.2 Cases 
The cases included in this stage varied depending on the SNP.  
All four SNPs (rs1497205, rs254348, rs4523255 and rs3784262) were genotyped in 6 
cohorts: the Levine Discovery, Levine Replication, our Discovery, UKREP1, Dutch 
Replication (including Extension) and UKREP2.  
After meta-analysis at this stage one SNP (rs3784262) was the most significant and 
was therefore additionally genotyped in the Irish Replication, UKREP3 and Belgian 
Replication samples (total number of cohorts for rs3784262=9). 
8.9.3.3 Genotyping 
SNPs selected for genotyping in Replication Phases 1, 2 and/or 3 were genotyped 
using the KASP genotyping technology (section 8.3.2.4) [141]. 
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8.9.4 Imputation 
Imputation was completed by Dr Claire Palles. To compensate for inter-study 
differences in array content, SNP genotypes were phased using SHAPEIT (to 
determine the haplotypes; which allele belongs to which copy of a specific 
chromosome or which alleles appear together on the same chromosome) and imputed 
(to estimate genotypes of individuals with missing data, using known haplotypes) using 
IMPUTE2 using recommended software options. The September 2013 release of the 
1000 genomes project was used as a reference panel. SNPs with IMPUTE2 info 
scores of <0.95 or showing departures from Hardy-Weinberg equilibrium (P<10−6) were 
excluded.  
8.9.5 Principle Component Analysis 
Principle Component Analysis (PCA) of our amended Discovery set (1,852 AspECT 
cases and 1,898 controls from CFR1 and CORGI), completed by Dr Claire Palles, was 
used to remove outlying samples, leaving 1,741 cases and 1,642 controls for analysis. 
λGC was 1.077 prior to the inclusion of the first principle component (PC) and 1.068 
after adjustment, suggesting that population structure was not a major confounder in 
our discovery phase. 
8.9.6 Association Testing and Meta-analysis 
Association testing and meta-analysis for the Levine SNPs was completed in the same 
way detailed in section 8.5, using SNPTEST and GWAMA [143]. 
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9. RESULTS 
As outlined in methods, Discovery and Replication Phases 1 and 2 sample sets within 
this project have been used in the initial BE GWAS paper by Su et al (2012) [2]. 
Discovery, UKREP1, Dutch Replication, UKREP2 and the Irish Replication have been 
used previously to identify two BE SNPs (rs9257809; P=4.09×10-9, OR=1.21 and 
rs9936833; P=2.74×10-10, OR=1.14). However, the Replication Phase 2 sample sets 
were only used to validate two SNPs in the previous GWAS. In this replication study, 
the SNP selection criteria for Replication Phase 2 samples were relaxed to P<10-4 
rather than P<10-8, resulting in analysis of 83 SNPs. An overview of the sample sets 
and number of SNPs analysed is shown in Figure 9.1. 
9.1 IDENTIFICATION OF TWO NOVEL BE SNPS 
9.1.1 SNPs Prioritised for Replication in Phase 2 Samples 
Three custom Sequenom iPLEXes were designed by Dr Claire Palles at the WTCHG. 
A total of 83 SNPs were prioritised for further genotyping based on the following criteria: 
(i) P<10−4 in combined Discovery and Replication Phase 1 analysis in Su et al 
(2012) [2] (N=63) 
(ii) P<10−4 in Discovery Phase, but not included in Replication Phase 1 in Su et al 
(2012) [2] (N=12) 
(iii) P<10−4 in a sex-stratified analysis of the Discovery phase (N=5) 
(iv) Candidate polymorphisms previously reported as associated with BE and not 
well tagged by the Discovery Phase or Replication Phase 1 (N=3) 
Assays were successfully designed for 65 of the 83 SNPs (details can be found in 
Section 8.4.1). These SNPs were genotyped in the Replication Phase 2 samples; 
UKREP2 set (1,765 cases and 1,586 controls) and the Irish set (245 cases and 473 
controls). A meta-analysis of the Discovery and Replication Phases 1 and 2 was 
completed by Dr Claire Palles (results produced by Dr Claire Palles can be found in the 
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appendix, Table 11.1). A selection of these SNPs (N=12) were selected for replication in 
Phase 3 samples.  
 
Figure 9.1: Outline of the phases and the SNPs analyzed [1]. Discovery and Replication Phase 1 were used in the 
previous GWAS by Su et al [2]. Two SNPs described in Su et al [2] had previously been genotyped in Replication Phase 2 
and BEACON/BEAGESS samples. Replication Phase 3 samples are new to this replication study. Dutch Replication 
(Phase 1 Replication) and the Dutch extension (Phase 3 Replication) is one cohort in our analyses for the SNPs taken 
through to Replication Phase 3. *11 SNPs: Our SNPs; rs3072, rs6751791, rs2731672, rs2701108, rs189247, rs2043633, 
and rs12985909 and Levine et al [3] SNPs; rs1497205, rs254348, rs3784262, and rs4523255. +8 SNPs: Our SNPs: 
rs3072, rs6751791, rs2731672, rs2701108, rs189247, rs2043633, and Levine et al SNP: rs3784262. Δ7 SNPs: Our SNPs: 
rs3072, rs6751791, rs2731672, rs2701108, rs189247, rs2043633. 
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9.1.2 SNPs Prioritised for Replication in Phase 3 Samples 
SNPs selected for genotyping in Replication Phase 3 samples were based on a meta-
analysis between Discovery set and Replication Phase 1 samples published in Su et al 
(2012) [2] with Replication Phase 2 samples. Following meta-analysis, 12 SNPs met 
the arbitrary cut off of P<5x10-6, shown in Table 9.1. Five SNPs were excluded from 
further replication. rs7255 had a call rate <95% on the Sequenom iPLEX, and was also 
in LD (r2=0.51) with rs3072 (which had a more significant P value at this stage), so was 
excluded. rs9936833 was excluded from replication as it is a previously reported BE 
susceptibility SNP [2]. rs12993283 was excluded as it was in complete LD with 
rs6751791 (r2=1.00).  
SNP   
C
H 
R 
  Position    Meta OR   Excluded   Reason for Exclusion 
rs3072  2  20741887  1.15  No  -  
rs2043633  16  5759275  1.15  No  - 
rs7255  2  20742301  1.15  Yes  
<95% call rate and in LD 
with rs3072 (r2=0.51) 
rs9936833  16  84960619  1.15  Yes  
Previously reported BE 
susceptibility SNP 
rs189247  15  95387634  1.14  No  - 
rs2701108  12  1.13E+08  1.14  No  - 
rs6751791  2  35435501  1.14  No  - 
rs12993283  2  35445909  1.12  Yes  
In LD with rs6751791 
(r2=1.00)  
rs9941024  16  5734313  1.12  Yes  
In LD with rs2043633 
(r2=0.75) 
rs2731672  5  1.77E+08  1.14  No  - 
rs12985909  19  18300383  1.11  No  - 
rs11866983   16   5743925   1.12   Yes   In LD with rs2043633 (r2=0.42) 
Table 9.1: SNPs selected for Phase 3 Replication, based on meta-analysis between Discovery 
and Replication Phases 1 and 2. Twelve SNPs, ranked by P-value, with P<5x10
-6
 after meta-analysis 
between Discovery and Replication Phases 1 and 2. Five SNPs were excluded from Replication Phase 
3. Chr, Chromosome; LD, Linkage Disequilibrium; OR, Odds Ratio. 
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 rs9941024 and rs11866983 were in LD with rs2043633 (r2=0.75 and 0.42 respectively), 
hence only rs2043633 was carried forward to Replication Phase 3 (as it had the 
strongest association after Discovery and Replication Phases 1 and 2 meta analysis).  
The seven remaining SNPs (rs3072, rs2043633, rs189247, rs2701108, rs6751791, 
rs2731672, rs12985909) were therefore genotyped in all Replication Phase 3 samples; 
UKREP3 (997 cases and 974 controls), Dutch Extension (64 cases and 206 controls), 
Belgian (362 cases and 848 controls) and BEACON (3295 cases and 3204 controls) 
sets.  
9.1.3 Power Calculations for UKREP3 and Replication Phase 3 
Power calculations are an important tool when determining the probability that a 
statistical significance test will reject the null hypothesis. Within this study, power 
calculations were determined using the Cochran-Armitage Trend test, as this is the 
most frequently used in genotype-based tests for case-control genetic association 
studies. Results from these calculations in UKREP3 (997 cases and 974 controls) and 
all Phase 3 replication samples (4697 cases and 5205 controls) can be seen in Table 
9.2. From Table 9.2, it is clear that there is not significant power (>0.80) to determine a 
SNP 
C 
H 
R 
Position Discovery MAF (cases/controls) 
Effect 
Size*  
Case:control 
ratio+ 
Cochran-
Armitage 
Trend 
Test 
rs3072 2 20878406 0.41/0.36 1.16 UKREP3 1.02:1 0.62 
Rep3 0.90:1 1.00 
rs6751791 2 35581997 0.51/0.48 1.13 UKREP3 1.02:1 0.48 
Rep3 0.90:1 0.99 
rs2731672 5 176842474 0.27/0.24 1.14 UKREP3 1.02:1 0.43 
Rep3 0.90:1 0.98 
rs2701108 12 114674261 0.38/0.41 1.14 UKREP3 1.02:1 0.53 
Rep3 0.90:1 1.00 
rs189247 15 97586630 0.41/0.37 1.14 UKREP3 1.02:1 0.52 
Rep3 0.90:1 0.99 
rs2043633 16 5819274 0.37/0.41 1.15 UKREP3 1.02:1 0.58 
Rep3 0.90:1 1.00 
rs12985909 
  
19 
 
18439383 
 
0.48/0.45 
 
1.12 
 
UKREP3 1.02:1 0.43 
Rep3 0.90:1 0.98 
Table 9.2: Power calculations, for the seven SNPs taken through to Replication Phase 3, in UKREP3 
samples and all Replication Phase 3 samples. Position is based on build 37. *Effect Size was determined by 
meta-analysis of Discovery, Replication 1 and Replication 2. + The case:control ratio stated was determined in 
the Discovery phase. UKREP3 consisted of 997 cases and 974 controls. Replication Phase 3 (Rep3) consisted 
of 4697 cases and 5205 controls. MAF, Minor Allele Frequency. 
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true variation when using the UKREP3 sample set. The SNP with greatest power is 
rs3072 (power = 0.62). However, when all Replication Phase 3 samples are used, 
there is significant power to determine a true variation for all seven SNPs. This 
highlights the importance of sample size. 
9.1.4 Meta-analysis of Discovery and the three Replication Phases 
SNP association analysis of the seven SNPs in only the UKREP3 sample set (997 
cases and 974 controls) can be seen in Table 9.3. rs3072 is significant in the single 
UKREP3 set with P=0.018, OR=1.18, 95%CI=1.04-1.34, all other SNPs show no 
significance in this sample set (P<0.05). This result is not unexpected, since the power 
calculation (section 9.1.3) showed that rs3072 was the most likely (out of the seven 
SNPs tested) to show significance in the UKREP3 sample set, as it had the greatest 
power. 
9.1.4.1 Corrections for Multiple Testing 
A P value threshold of 0.05 has been accepted as a reasonable level for declaring 
significance. When this threshold is enforced, the chance of making a Type I error 
SNP   
C 
H 
R 
  Position   EA   OR (95%CI)   P 
rs3072 
 
2 
 
20878406 
 
G 
 
1.18 (1.04-1.34) 
 
1.18x10-2 
rs6751791 
 
2 
 
35581997 
 
G 
 
1.02 (0.86-1.20) 
 
8.04x10-1 
rs2731672 
 
5 
 
176842474 
 
A 
 
1.02 (0.85-1.24) 
 
8.13x10-1 
rs2701108 
 
12 
 
114674261 
 
A 
 
1.03 (0.91-1.16) 
 
6.69x10-1 
rs189247 
 
15 
 
97586630 
 
A 
 
1.07 (0.94-1.22) 
 
2.80x10-1 
rs2043633 
 
16 
 
5819274 
 
C 
 
1.03 (0.90-1.17) 
 
6.83x10-1 
rs12985909   19   18439383   G   1.03 (0.91-1.16)   6.47x10-1 
Table 9.3: SNP association analysis of the seven SNPs in the UK Replication 3 sample set 
consisting of 997 Barrett’s Oesophagus cases and 974 female controls. Results are presented with 
respect to the effect allele. Chr, Chromosome; EA, Effect Allele; OR, Odds Ratio; 95%CI, 95% Confidence 
Intervals; P, P value. 
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(falsely claiming significance) is 5% (α=0.05). This 5% error rate applies to each 
statistical test run. Therefore, the more analyses run, the higher the chance of Type I 
error. 
One way to correct for multiple testing in GWAS is the Bonferroni correction. The 
Bonferroni correction adjusts alpha to 0.05/n, where n is the number of statistical tests 
performed. Most GWAS use genotyping platforms which test for 1,000,000 SNPs; 
hence the statistical significance threshold of a single SNP association in a GWAS is 
set at 5×10−8 [151-154]. 
9.1.4.2 Meta-analysis  
 Meta-analysis of the Discovery and the three Replication phases, seen in Table 9.4, 
identified two intergenic SNPs associated with BE risk, from a total sample size of 
10,158 BE cases and 21,062 controls. rs3072 on chr2p24: Pmeta=1.8×10−11; OR=1.14; 
95%CI=1.09-1.18 and rs2701108 on chr12q24: 7.5×10−9; OR=1.11; 95%CI=1.08-1.16.
SNP   
C 
H 
R 
  Position    EA   OR (95%CI)   P 
rs3072  2  20878406  G  1.14 (1.09-1.18)  1.75×10
−11 
rs6751791  2  35581997  A  1.08 (1.04-1.12)  7.65×10
−5 
rs2731672  5  176842474  A  1.07 (1.03-1.12)  1.66x10
-3 
rs2701108  12  114674261  A  1.11 (1.08-1.16)  7.48×10
−9 
rs189247  15  97586630  A  1.10 (1.06-1.14)  3.55×10
−7 
rs2043633  16  5819274  A  1.09 (1.05-1.14)  2.25×10
−6 
rs12985909   19   18439383   G   1.10 (1.06-1.14)   3.28×10−7 
Table 9.4: Final meta-analysis of all sample sets for the seven SNPs taken through to Replication 
Phase 3. Results are presented with respect to the effect allele. Position is based on build 37. Results 
based on meta-analysis of all sample sets comprising UK Discovery, UK Replication 1, Dutch Replication 
and Extension, Irish Replication, UK Replication 2, UK Replication 3, Belgian Replication and the 
BEACON Replication. Chr, Chromosome; EA, Effect Allele; OR, Odds Ratio; 95%CI, 95% Confidence 
Intervals; P, P value after meta-analysis. 
83 
9.1.5 Restricting cases to Intestinal Metaplasia for the two novel SNPs 
The standard UK criteria, in accordance with the British Society of Gastroenterology, for 
the diagnosis of BE was used throughout this study [53]. However, the American College 
of Gastroenterology criteria are used in other countries, which requires the presence of 
IM for diagnosing BE. Therefore, in order to investigate the effect of including non-IM 
cases, the meta-analysis was restricted to IM-only individuals (N=8,521). The results 
show that the associations remained at or near genome-wide significance (P<5×10−8; 
rs3072: P=1.3×10−9, OR=1.13, 95%CI=1.09-1.17; rs2701108: P=6.2×10−8, OR=1.11, 
95%CI=1.08-1.16) when compared to the meta-analysis comprising all IM positive and 
negative cases (rs3072: Pmeta=1.8×10−11, OR=1.14, 95%CI=1.09-1.18; rs2701108: 
7.5×10−9; OR=1.11; 95%CI=1.08-1.16). 
9.1.6 Imputation of SNPs within 1Mb of the novel SNPs 
To assess the disease-association strength of the genotyped SNPs, the Discovery 
phase data was imputed for all SNPs within 1Mb each side of the chr2p24 and 
chr12q24 intergenic hits (Figure 9.2). Imputation of our data, completed by Dr Claire 
Palles, showed that at chr2p24, rs3072 remained the most significant SNP. However, 
at chr12q24, rs1920562 (r2=0.6) was more significant (PDiscovery=1.4×10−5, OR=0.84) 
compared to the lead genotyped SNP (PDiscovery=1.4×10−3, OR=0.88).  
9.1.7 Identification of nearby Genes 
Using the Ensembl Genome Browser (http://www.ensembl.org), it was noted that 
rs3072 lies 7.5kb downstream of GDF7 (Growth Differentiation Factor 7, also known as 
BMP12; Bone Morphogenetic Protein 12) and 6.5kb downstream of C2orf43 
(chromosome 2 open reading frame 43). rs2701108 lies 117kb downstream of TBX5 
(T-Box 5; transcription factor) and 270kb upstream of RBM19 (RNA binding motif 
protein 19) (Figure 9.2). Whilst the imputed, more significant SNP at this locus, 
rs1920562, lies 131kb downstream of TBX5 and 256kb upstream of RBM19.  
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Figure 9.2: Regional plots of association (left y-axis) and recombination rates (right y-axis) for the 
chromosomes 2p24 and 12q24 loci following imputation [1]. rs3072 remains most significant in the 
chr2 region, but rs1920562 is more significant than rs2701108 in the chr12 region. The lead genotyped 
SNP is marked with a purple square. Imputed SNPs are plotted as circles and genotyped SNPs as 
squares.
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9.1.8 Assessment of Non-Synonymous SNPs within nearby Genes 
Non-synonymous variants (mutations which alter the amino acid sequence of a protein) 
in the genes near the SNPs on chr2 and chr12 were not in strong LD (r2<0.4) with the 
newly identified SNPs (rs3072 and rs2701108). This suggests that the novel SNPs may 
not have associations with known non-synonymous SNPs, but they could have an effect 
on gene expression/regulation rather than the protein sequence itself. 
9.1.9 In silico Functional Analysis of the Two Novel BE-associated SNPs 
There are a variety of databases that can be used to predict function and effect of 
intronic SNPs. For the two novel BE-associated SNPs (rs3072 and rs2701108), 
HaploReg [146], RegulomeDB [147], Annovar [149] and SCAN [148] were interrogated. 
In order to gain a true sense of function or effect of SNPs at these loci, variants in LD 
with the two novel BE SNPs (r2>0.4) were determined using the HaploReg database. 
Each SNP list was used to determine predicted effects and sequence conservation of 
the two novel SNPs. 
9.1.9.1 rs3072 Analysis 
The first BE-associated SNP, rs3072, is located in a region of histone modifications 
that marks enhancers, such as H3K4Me1, between genes GDF7 and C2orf43 (as can 
be seen in Figure 9.3 using the UCSC Genome Browser [5]). This data was collected 
from the lymphoblastoid cell line (LCL), GM12878. Histone modifications, such as 
H3K4Me1, are associated with active regions (i.e. involved in/important for transcription) 
of the genome; H3K4Me1 in particular is one of the most robust epigenetic marks that 
appears to be essential for the regulation of different cellular processes [155]. 
According to HaploReg, rs3072 was listed as having the potential to alter a GATA 
binding motif (a family of transcription factors). Details of the motif change can be seen 
in Table 9.5 (Table 9.5B shows the nucleotide coding used in Table 9.5A). However, 
RegulomeDB found “minimal binding evidence” for the bound protein RFX3, a 
transcription factor important in the regulation of the expression of genes involved in 
ciliary assembly and motility [156].  
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!
!
rs3072!
! ! ! ! ! !
Regulatory!
Motif!
Strand! Ref:!TGCAGCTTAGAAAGCAAATTTCATCTGATTCCAGTACTGTGATTTTAAGGAAACGGTAA!
Alt:!!TGCAGCTTAGAAAGCAAATTTCATCTGATCCCAGTACTGTGATTTTAAGGAAACGGTAA!
GATA! +! !! !!!!!!!!!!!!!!!!!!!!!!!!!!!ABCTGATM! !!
! ! ! ! ! ! !
rs9306894! ! ! ! ! ! !
Regulatory!
Motif!!
Strand! Ref:!TTTCTTTGACGAAGAATCATAATTGAGTCACTTTAGGTCTTTTAGCTGGAAGCATTTCA!
Alt:!!TTTCTTTGACGAAGAATCATAATTGAGTCGCTTTAGGTCTTTTAGCTGGAAGCATTTCA!
AP:1! :! ! !!!!!!!!!!!!!!!!!!!!!WMKKAGTCABY! !
AP:1! :! ! !!!!!!!!!!!!!!!!!!!!!!!!!!!!!TGAKTCA! !
AP:1! +! !! !! !!!!!!!!!!!!!!!!VTGACTHA!
 
 
 
 
 
 
 
 
Three additional SNPs in LD with rs3072 (rs9306894, r2=0.97; rs9306895, r2=0.97; and 
rs7255, r2=0.60) map to the enhancer region detected in GM12878, as can be seen in 
Table 11.5. Using ANNOVAR, GERP and PhastCons scores showed that rs7255 
mapped to a site of high evolutionary conservation (GERP=2.28, PhastCons=501), 
suggesting important function for this base/region. Neither of the other two SNPs within 
the same enhancer region showed conservation. RegulomeDB showed that rs9306894, 
Nucleotide!code! Possible!Nucleotides!
R! A!or!G!
Y! C!or!T!
K! G!or!T!
M! A!or!C!
S! G!or!C!
W! A!or!T!
B! G!or!C!or!T!
D! A!or!G!or!T!
H! A!or!C!or!T!
V! A!or!C!or!G!
Table 9.5: Regulatory motif changes predicted by HaploReg for the BE susceptibility SNP rs3072 
and one SNP in LD, rs9306894 (r2=0.97). (A) Each SNP is denoted by bold font. rs3072 is predicted to 
alter a GATA binding motif according to HaploReg (top). rs9306894, according to both HaploReg and 
ReglomeDB, has the potential to alter the binding motif of Activator Protein 1 (AP-1; bottom). (B) The 
ambiguous nucleotide codes are specified in Table9.4B. 
A: 
B: 
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although not at a conserved site, is predicted as “likely to affect protein binding and 
linked to expression of a gene target”. This database also showed that C2orf43 is the 
most likely target of rs9306894 following eQTL studies in monocytes. Both 
RegulomeDB and HaploReg show that rs9306894 also has the potential to affect an 
AP-1 binding motif (a transcription factor important in the regulation of proliferation, 
differentiation and apoptosis). rs9306895 has “minimal binding evidence” according to 
RegulomeDB. Neither database could agree on a possible change in binding motif for 
this SNP. None of the three SNPs were associated with GDF7 (the nearest protein 
coding gene) expression.  
Another SNP in LD with rs3072, rs13385191 (r2=0.46), achieved a GERP score of 2.86 
and had “minimal binding evidence” according to RegulomeDB. SCAN showed that this 
SNP was located within an intron of C2orf43. RegulomeDB also showed that C2orf43 
is the most likely target of this SNP following eQTL studies in fibroblasts.  
The Human Protein atlas shows the level of GDF7 RNA expression at 1FPKM, but 
protein expression was not recorded. It also shows that C2orf43 RNA expression is 
14FPKM and the protein is expressed at a medium level in the oesophagus. 
An overview of the data can be found in Figure 9.3 and in the appendix (Table 11.5). 
9.1.9.2 rs2701108 Analysis 
Analysis of the second BE-associated SNP, rs2701108 (located between genes TBX5 
and RBM19), using three of the four databases showed that it is not likely to be a 
functionally regulatory SNP itself. However, HaploReg did predict rs2701108 to affect 
the binding of the TBX5 protein (Table 9.6). When comparing the genotyped SNP to 
those in LD, it appears as though rs1920562 (r2=0.62), the SNP that showed the 
strongest signal upon imputation of the chr12q24 loci (section 9.1.6), is a more 
promising candidate. rs1920562 maps to a highly conserved base (PhastCons score = 
556) and a region containing enhancer marks in human embryonic stem cells (h1-ESC) 
and lung fibroblasts (NHLF), as seen in Figure 9.4. 
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rs2701108!
! ! ! ! ! ! ! !Regulatory!
Motif! Strand!
Ref:!ATTCAGGCAGGAGAAAATGTGTACTCTCATCTTTTCCAGAGTCACCTAGGAGGCAGGGC!
Alt:!!ATTCAGGCAGGAGAAAATGTGTACTCTCACCTTTTCCAGAGTCACCTAGGAGGCAGGGC!
TBX5! :!
! !
!!!!!!!YTCACACCTK!
! ! !
! ! ! ! ! ! ! ! !rs1950090!
! ! ! ! ! ! ! !Regulatory!
Motif! Strand!
Ref:!CAGCTACAATGGGCATGTGACTCAGGGTGACCAATCACAGCTCCTCCCTGCCTTAGGGA!
Alt:!!CAGCTACAATGGGCATGTGACTCAGGGTGGCCAATCACAGCTCCTCCCTGCCTTAGGGA!
NF:Y! :!
! !
!!!!!!!!!!NBYRRCCAATSRRMR!
! ! !NF:Y! +!
! !
!!!!!!!!!!!!VBBRRCCAATSRSVDN!
! ! !NF:Y! +!
! !
!!!!!!!DBTARCCAATCARD!
! ! !
! ! ! ! ! ! ! ! !rs12828548!
! ! ! ! ! ! ! !Regulatory!
Motif! Strand!
Ref:!AAGTGGAGATCCAATTCCTTCTTCCAATACGTTTGTTATTTCTAAATAGCAACTCAGCT!
Alt:!!AAGTGGAGATCCAATTCCTTCTTCCAATAGGTTTGTTATTTCTAAATAGCAACTCAGCT!!
FOXJ1! +!
! !
!!!!!!HWDTGTTTGTTTA!
! ! !RAD21! :!
! !
!!!DMCACYAGGT!
! ! !ZFP105! :!
! !
!!HNHWTKTTDWTTRHD!
! !
! ! ! ! ! ! ! ! !rs1920568!
! ! ! ! ! ! ! !
Regulatory!
Motif! Strand!
Ref:!TCTCCTAGGAACTGTAAGTTATGTCCTTCGTGCCTTTCTGAAAACCATCTTAAGCTGTT!
Alt:!!TCTCCTAGGAACTGTAAGTTATGTCCTTCCTGCCTTTCTGAAAACCATCTTAAGCTGTT!!
EWSR1:FLI1! :!
! !
!CCTTCCTTCCTTCCTTCC!
! ! !ETS! :!
!
!!!!!!!!!!!!!!!!!!!!!!!!!!!DBKNRCWTCCKSYBHN!
! ! !STAT! :!
! !
!!!!!!!!!!!!!WTCCTSCCT!
! ! !
Table 9.6: Regulatory motif changes predicted by HaploReg for the BE susceptibility SNP rs2701108 and 
three SNPs in LD, rs1950090 (r2=0.42), rs12828548 (r2=0.62) and rs1920568 (r2=0.58). Each SNP is denoted by 
bold font. rs2701108 is predicted to affect the binding of Transcription Box 5 (TBX5) according to HaploReg. 
rs1950090 is predicted to alter the binding motif of Nuclear Factor Y (NF-Y) according to both RegulomeDB and 
HaploReg. rs12828548 is predicted to alter the binding motifs of Forkhead box protein J1 (FOXJ1), RAD21 and 
Zinc Finger Protein 105 (ZFP105). rs1920568 is predicted to alter the motif of  EWSR1/FLI1 (Ewing sarcoma 
breakpoint region 1/Friend leukemia integration 1 transcription factor; a chimeric fusion oncogene), E26 
transformation-specific (ETS) and Signal Transducer and Activator of Transcription (STAT).  
The ambiguous nucleotide codes are specified in Table 9.4B. 
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As can be seen in Table 11.6, the highest scoring SNPs in LD with rs2701108 
according to RegulomeDB were: rs1247938 (r2=0.52), rs1920562 (r2=0.62) and 
rs1950090 (r2=0.42). CCCTC-binding factor (CTCF; a zinc finger protein involved in 
transcriptional repression) and the double-strand-break repair protein rad21 homolog 
(RAD21) binding are predicted to be affected by rs1247938 according to RegulomeDB, 
HaploReg and the UCSC Genome Browser (Figure 9.4 and Figure 9.5). The ability of 
IKAROS Family Zinc Finger 1 (IKZF1) binding is predicted to be altered by rs1920562 
according to RegulomeDB, but no evidence of this was present via HaploReg or the 
UCSC Genome Browser. According to the UCSC Genome Browser, rs1920562 lies 
within a region of conservation, seen in Figure 9.4. rs1950090 is predicted to affect the 
binding of USF1 (Upstream stimulatory factor 1), BCL3 (B-cell lymphoma 3-encoded 
protein; a proto-onocogene) and NF-Y (Nuclear Factor Y; a transcription factor) 
according to RegulomeDB and HaploReg. The UCSC Genome Browser identified 
three additional binding motif changes (seen in Figure 9.4 and Figure 9.6): Nuclear 
Transcription Factor Y, beta subunit (NFYB), Nuclear Factor 1 (NFIC) and Nuclear 
Factor of Activated T-cells, Cytoplasmic 1 (NFATC1). 
Sequence conservation (GERP score>2) was shown at three SNPs in LD with 
rs2701108: rs12828548 (r2=0.62, GERP=2.1), rs2555019 (r2=0.52, GERP=2.13) and 
rs1920568 (r2=0.58, GERP=2.29). According to RegulomeDB, rs12828548 has 
“minimal binding evidence” and is predicted to alter the FOXA2 binding motif. However, 
according to HaploReg, the SNP is predicted to alter binding motifs of RAD21, FOXJ1 
and ZFP105 (the latter two of which are transcription factors), as seen in Table 9.6. 
Unfortunately the UCSC Genome Browser does not support this prediction. 
rs12828548, according to RegulomeDB, HaploReg and the UCSC Genome Browser, 
lies within an enhancer region of histone modifications (Figure 9.4). rs2555019, 
similarly to the previous SNP, has “minimal binding evidence” according to 
RegulomeDB. RegulomeDB also predicts that this SNP alters a GATA binding motif, 
however this is not supported by HaploReg or the UCSC Genome Browser. Whilst 
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there is no data for rs1920568 on RegulomeDB, HaploReg predicts a motif change in 
EWSR1/FLI1 (Ewing sarcoma breakpoint region 1/Friend leukemia integration 1 
transcription factor; a chimeric fusion oncogene), ETS and STAT (Table 9.6).  
An overview of this data can be found in the appendix; Table 11.6. 
9.2 SNP ASSOCIATION TESTING OF THE FOUR BE VARIANTS IN EAC-
ONLY CASES 
BE is a known pre-cursor of EAC. To investigate whether the SNPs identified as BE 
risk were also linked to EAC, an independent set of 305 UK and 176 Dutch samples, 
reported as EAC-only were used. Four SNPs were analysed: the two newly identified 
SNPs (rs3072; chr2p24 and rs2701108; chr12q24) and the two previously reported in 
Su et al (2012) [2] (rs9257809; chr6p21 and rs9936833; chr12q24).  
 The first stage of the analysis compared EAC-only to Replication Phase 1 controls; no 
! ! ! ! !
EAC cases  
v  
Controls 
!
BE cases  
v  
EAC cases 
SNP 
C 
H 
R 
Position  Alleles* 
St
at
is
tic
 
UK Dutch Meta   UK Dutch Meta 
rs3072 2 20741887 G/A 
OR 1.13 1.04 1.10 
 
1.01 1.14 1.05 
P 0.17 0.72 0.18 0.89 0.30 0.48 
rs9257809 6 29464310 G/A 
OR 1.05 0.79 0.95 
  
0.75 0.85 0.78 
P 0.72 0.16 0.57 0.04 0.46 0.03 
rs2701108 12 1.15E+08 G/A 
OR 1.11 1.00 1.07 
 
0.80 0.94 0.84 
P 0.23 0.98 0.34 0.01 0.63 0.02 
rs9936833 16 84960619 C/T 
OR 1.12 1.15 1.13 
  
1.08 0.93 1.03 
P 0.19 0.25 0.08 0.38 0.58 0.66 
Table 9.7: Analysis of the four Barrett’s Oesophagus SNPs at genome wide significance in our 
studies in Oesophageal Adenocarcinoma-only cases compared with Replication Phase 1 controls 
and compared to Replication Phase 1 Barrett’s Oesophagus cases. *Alleles are presented as 
minor/major. Positions are based on build 36. All results are presented in respect to the minor allele.  EAC-
only cases (UK N=305; Dutch N=176) had not been included in the BE case analysis.  UK BE cases were 
from Discovery and UK Replication Phase 1 (N=2,957).  Dutch BE cases were from Replication Phase 1 
(N=473).  Controls were from Replication Phase 1 (UK N=6,819; Dutch N=1,780). Chr, Chromosome; OR, 
Odds Ratio; P, P value. Note that the direction of effect for rs2701108 in the EAC-only-control analysis was 
the opposite of that for BE in the GWAS. 
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SNP was associated with EAC risk (P<0.05). The second stage of the analysis 
compared EAC-only cases to Replication Phase 1 BE cases; two SNPs (rs9257809 
and rs2701108) were significant (P<0.05) when comparing BE to EAC cases 
(Pmeta=0.03 and 0.02 respectively; Table 9.7).  
9.3 REPLICATION OF BE/EAC SNPS REPORTED BY LEVINE ET AL (2013) 
[3] 
Whilst completing this research project, a combined BE/EAC GWAS paper was 
published by Levine et al (2013) [3]. The paper analysed a total 922,031 SNPs in the 
Discovery phase and 87 of 94 SNPs with P<1×10−4 in the replication phase, identifying 
four SNPs (three loci) associated with BE/EAC risk. The four BE/EAC SNPs reported 
were: rs2687201, rs11789015, rs10419226, and rs10423674. 
9.3.1 Replication Analysis of the Four BE/EAC SNPs 
Due to an overlap in controls between the Levine study and our Discovery (the WTCCC2 
controls), new UK CORGI controls [127] were employed for our Discovery set (details in 
Section 8.9.1).  
When Levine et al (2013) [3] restricted their analysis to BE-only cases (without EAC) 
none of the four SNPs listed above were genome-wide significant (P<5×10−8), although 
one SNP (rs10419226 within CRTC1) reached P=5.5×10−8.  
When replicating the four SNPs detailed above, one SNP (rs10423674) had already 
been genotyped in our Discovery set. The remaining three SNPs had to be imputed. All 
SNPs were analysed in the Levine Discovery, Levine Replication and our own Discovery 
(Number of studies = 3). rs10423674 was also already typed on the Immunochip in 
UKREP1 and the Dutch Replication (Number of studies = 5; Table 9.8). 
Of the four BE/EAC associated SNPs, two were supported in our samples: rs2687201, 
located near FOXP1, and rs10423674, one of two SNPs located in CRTC1 (P=0.02, 
OR=1.14, 95%CI 1.03-1.27 and P=0.05, OR=0.94, 95%CI 0.88-1.00 respectively).  The 
direction of effect for rs11789015 (located in BARX1) was the same in both studies, 
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however the P value in our study, albeit close to the 0.05 significance criteria, was not 
significant; hence there appears to be limited support for this SNP (P=0.07, OR=0.90, 
95%CI 0.81-1.01). However rs10419226, the second SNP located in CRTC1, was not 
replicated in our data (P=0.87, OR=1.01, 95%CI 0.91-1.11).  
Meta analysis between the Levine BE/EAC data with our BE data (without EAC) showed 
association improvement in three of the four SNPs (rs2687201, rs11889015 and 
rs10423674), maintaining their genome-wide significance (P<5×10−8) (Table 9.8). 
However, association of rs10419226 worsened, although it was still genome-wide 
significant upon addition of our data (P=1.17×10−8, OR=1.14, 95%CI 1.09-1.19). 
A meta-analysis between the Levine BE data (without EAC) with our BE data (without 
EAC) showed association improvement, with P values closer to the P<5×10−8 threshold, 
in three out of the four SNPs (rs2687201, rs11889015 and rs10423674). rs2687201, 
near FOXP1 reached genome-wide significance (P=4.61×10−8, OR=1.16, 95%CI=1.10-
1.23). However, the significance of rs10419226 worsened with the addition of our data 
(P=2.14×10−6, OR=1.13, 95%CI 1.08-1.20; Table 9.8).  
9.3.2 Replication Analysis of the Remaining 83 BE/EAC SNPs 
The remaining 83 SNPs with P<10−4 in the BE/EAC study (Supplementary Table 3 of 
Levine et al (2013) [3]) were then analysed in our Discovery data to see if the inclusion 
of our data increased the significance of any variant. Of these, 73 were directly 
genotyped in our Discovery samples or were imputed with an info score of >0.95. Of 
the 10 remaining SNPs that could not be imputed with high quality, only one had 
P<10−5 in the original Levine data; we therefore genotyped this SNP (rs11771429) 
using KASPar in our Discovery cases and controls. The remaining 9 SNPs were not 
analysed. Therefore, a total of 74 SNPs were analysed in our Discovery set. 
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The data was then combined by meta-analysis with the Levine BE/EAC data and our 
UK Discovery data. Of the 74 SNPs, six SNPs reached a P value <10−5. The six SNPs 
were rs1497205, rs254348, rs3784262, rs6479527, rs9837992 and rs4523255. 
However, the SNAP database showed that rs6479527 was correlated with one of the 
four BE/EAC associated SNPs, rs11789015 (r2=0.39), so is therefore unlikely to be an 
independent signal. Similarly, rs9837992 is in LD with rs2687201 (r2=0.96), another of 
the four BE/EAC SNPs. Hence, these two SNPs were not taken forward for further 
replication. The remaining 4 SNPs (rs1497205, rs254348, rs3784262 and rs4523255) 
were genotyped in our Replication Phase samples.  
All four of these SNPs were genotyped in the Levine Discovery, Levine Replication, UK 
Discovery, UKREP1, Dutch Replication and Extension (analysed as one sample set) 
and UKREP2 (number of studies=6).  rs3784262 was taken forward due to the P value 
nearing the significance threshold (P<5×10−8), and was genotyped in the Irish 
Replication, UKREP3 and the Belgium Replication (number of studies=9). 
Upon meta-analysis of the Levine BE/EAC data and our BE data, three out of the four 
SNPs (rs1497205, rs4523255 and rs3784262) showed improvement in their 
association. rs1497205 (located near PARM1) had a P value in the Levine data of 
1.28×10−5 (OR=0.87, 95%CI 0.82-0.93), now with a meta P value of 3.68×10−7 
(OR=0.90, 95%CI 0.86-0.94). rs4523255 (located near MFHAS1) had Levine P value of 
4.15×10−5 (OR=1.13, 95%CI 1.07-1.20), now with a meta P value of 9.24×10−6 
(OR=1.09, 95%CI 1.05-1.14). Whilst rs3784262 (located near ALDH1A2), with a Levine 
P value of 6.72×10−7 (OR=0.88, 95%CI 0.83-0.92), was now associated with BE/EAC 
risk with a meta P value of 3.72×10−9 (OR=0.90, 95%CI 0.87-0.93; Table 9.9).  
In a BE-only meta-analysis of the two studies, two out of four SNPs (rs1497205 and 
rs4523255) showed association improvement, with more significant P values upon 
addition of our samples. However, neither SNP was associated with a BE-only risk 
(P<5×10−8). rs1497205 had a Levine P value of 2.86×10−5 (OR=0.86, 95%CI 0.80-0.92), 
and a meta P value of 2.57×10−6 (OR=0.90, 95%CI 0.86-0.94). rs4523255 had a Levine 
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P value of 2.46×10−4 (OR=1.13, 95%CI 1.06-1.21) and a meta P value of 2.48×10−5 
(OR=1.09, 95%CI 1.05-1.14). The significance of the remaining two SNPs (rs254348 
and rs3784262) decreased upon addition of our BE data. The Levine P values for 
rs254348 and rs3784262 were 1.15×10−4 (OR=0.88, 95%CI 0.83-0.94) and 3.62×10−7 
(OR=0.85, 95%CI 0.80-0.90) respectively, with a meta P values of 5.49×10−4 (OR=0.93, 
95%CI 0.89-0.97) and 1.37×10−6 (OR=0.91, 95%CI 0.87-0.94) respectively (Table 9.9).
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10. DISCUSSION 
10.1 IDENTIFICATION OF NOVEL BE-ASSOCIATED SNPS 
As can be seen in Table 11.1, prior to Replication Phase 3, rs3072 was already 
genome-wide significant, with Pmeta=4.0×10−9, OR=1.15, 95%CI=1.11-1.20. However, 
rs2701108 was not significant, with Pmeta=1.4×10−7, OR=1.12, 95%CI=1.08-1.16, prior 
to Replication Phase 3.  
The addition of Replication Phase 3 samples (4697 cases and 5205 controls) has 
increased our power to detect true variations associated with BE. In our study, the 
inclusion of all Replication Phase 3 samples has increased the association signal of 
rs3072 and rs2701108. A meta-analysis of all data (with a total sample size of 10,158 
BE cases and 21,062 controls) has identified two intergenic SNPs associated with BE 
risk (P<5×10−8). The first SNP, rs3072, located on chr2p24, has Pmeta=1.8×10−11, 
OR=1.14, 95%CI=1.09-1.18. The second SNP, rs2701108, located on chr12q24, has 
Pmeta=7.5×10−9, OR=1.11, 95%CI=1.08-1.16. 
10.1.1 rs3072 Associated Genes and Theoretical Function 
The flanking genes of rs3072 are Growth Differentiation Factor 7 (GDF7; 7.5kb 
downstream) and Chromosome 2 Open Reading Frame 43 (C2ORF43; 6.5kb 
downstream). GDF7 (also known as Bone Morphogenetic Protein 12; BMP12) encodes 
the GDF7 (BMP12) protein, which is part of the Bone Morphogenetic Protein (BMP) 
family of Transforming Growth Factor β (TGFβ) superfamily proteins. There is evidence 
that this protein plays a role in the neural system and tendon/ligament development 
and repair, and also regulates signalling pathways that have the potential to impact on 
oesophageal development [157-159]. Any change in regulation or expression of this 
gene could, theoretically, influence the diaphragmatic tendon, which could predispose 
individuals to hiatal hernias. The presence of hiatal hernias increases the likelihood of 
reflux, a known risk factor for BE. C2ORF43 encodes the C2ORF43 protein and has 
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been implicated in prostate cancer susceptibility [160, 161], although there is no direct 
link to BE. 
Upon in silico functional analysis, rs3072 was found to lie within an enhancer region of 
histone modifications along with three other SNPs in LD (rs9306894, r2=0.97; 
rs9306895, r2=0.97; and rs7255, r2=0.60). rs3072 was found to alter a GATA 
(according to HaploReg) and Regulatory Factor X3 (RFX3; according to RegulomeDB) 
binding motif. GATA factors are zinc finger DNA binding proteins that regulate 
transcription; playing a role in proliferation, differentiation and apoptosis. Altered 
expression of GATA4, GATA6 and Indian Hedgehog (IHH; a GATA6 target) has 
already been identified in BE [162]. RFX3 is a transcription factor, encoded by the 
RFX3 gene, which contains a highly conserved winged helix DNA binding domain. It 
appears to play a role in the regulation of genes involved in ciliary assembly and 
motility [156] and has also been implicated in cell growth and carcinogenesis in the 
skin through Ras-signalling [163]. Although rs3072 does not appear to be at a 
conserved base or region after interrogation of the ANNOVAR database (GERP<2 and 
no PhastCons score), two SNPs in LD with rs3072 were (rs7255, r2=0.60 and 
rs13385191, r2=0.46). In particular, rs7255 is also predicted to be within the same 
enhancer region as rs3072, suggesting functional importance at this base (rs7255). 
eQTL studies in fibroblasts showed C2orf43 as the most likely target of rs13385191, an 
intronic SNP of C2orf43 according to RegulomeDB. C2ORF43 protein expression, 
determined via the Human Protein Atlas 
(http://www.proteinatlas.org/ENSG00000118961-C2orf43/tissue), was recorded as 
‘medium’ and RNA expression as 14FPKM. Unfortunately there was no protein 
expression data for GDF7, although RNA expression in the oesophagus was 1FPKM 
(http://www.proteinatlas.org/ENSG00000143869-GDF7/tissue). 
Although RegulomeDB identified C2ORF43 as the likely target of one SNP in LD with 
rs3072 (rs13385191, r2=0.46), the impact on GDF7 cannot be discounted, due to the 
lack of available expression data. When reviewing previous literature, GDF7 appears to 
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be the most likely target of rs3072 and/or SNPs in LD. The BMP family and TGFβ 
pathway have long been established as a possible mechanisms of BE, particularly in 
the transformation of normal oesophageal squamous cells into columnar cells [164, 
165]. 
10.1.2 rs2701108 Associated Genes and Theoretical Function 
The closest genes to the genotyped SNP, rs2701108, are T-Box 5 (TBX5; 117kb 
downstream) and RNA binding motif protein 19 (RBM19; 270kb upstream). Whilst the 
imputed, more significant SNP at this locus (rs1920562, r2=0.62), lies 131kb 
downstream of TBX5 and 256kb upstream of RBM19. TBX5 encodes the TBX5 protein, 
a member of the conserved family of genes, which share a DNA-binding domain (T-
box). TBX5 is an important transcription factor involved in developmental regulation 
and its protein is involved in heart and upper limb development. Mutations within the 
TBX5 gene have been associated with Holt-Oram syndrome (HOS) and Tetralogy of 
Fallot (TOF) syndrome, developmental disorders affecting the heart and upper limbs 
[166, 167]. This could in theory, be linked to BE, where abnormalities of the 
diaphragmatic musculature could predispose patients to hiatal hernias and acid reflux, 
two known BE risk factors [168, 169]. RBM19 encodes a nucleolar protein that contains 
six RNA-binding motifs. The RBM19 protein is thought to be involved in ribosome 
biogenesis and the regulation of proliferation, differentiation and cell fate decision in the 
intestinal epithelium [170] and has also been implicated in a combined HOS and ulnar-
mammary syndrome with TBX5 and TBX3 [171]. Therefore, if the expression of this 
gene was altered it could, theoretically, have a role in IM seen in some BE patients.  
At first glance, in silico functional analysis of rs2701108 suggests that it is not 
functionally important when compared to SNPs in LD. However, its importance may lie 
in HaploReg’s prediction of this SNP to alter a TBX5 binding motif. Whilst the imputed 
SNP, rs1920562, which had a stronger association upon imputation (PDiscovery=1.4×10−5, 
OR=1.19 compared to rs2701108: PDiscovery=1.4×10−3, OR=1.14), maps to a highly 
conserved base and a region containing enhancer marks. This suggests that the 
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imputed SNP is a more promising functional candidate, due to its conservation, instead 
of rs2701108.  
Whilst three other SNPs were also recorded as conserved (rs12828548, r2=0.62; 
rs2555019, r2=0.52; and rs1920568, r2=0.58), only rs12828548 lies within a region of 
histone modifications; suggesting functional importance for this particular SNP. 
However, predicted binding motif changes for rs12828548 are not consistent between 
RegulomeDB (FOXA2) and HaploReg (RAD21, FOXJ1 and ZFP105).  
Expression analyses in RegulomeDB did not suggest the target of the chr12q24 
variation, however, the Human Protein Atlas did provide protein and RNA expression 
data in the oesophagus. It recorded the TBX5 protein expression as ‘medium’ (with 
30/79 tissue cell types recorded as ‘medium’ or ‘high’) and RNA expression at 3FPKM 
(http://www.proteinatlas.org/ENSG00000089225-TBX5/tissue). Whilst the RBM19 
protein level was recorded at ‘medium’ (with 51/76 tissue cell types recorded as 
‘medium’ or ‘high’) and RNA expression levels at 8FPKM 
(http://www.proteinatlas.org/ENSG00000122965-RBM19/tissue). 
Whilst there is no definitive target of this variation within the selected databases, TBX5 
appears to be the most likely target, based on the current literature. In particular, 
diaphragmatic musculature abnormalities seen in patients with TBX5 variations are of 
interest due to the possible predisposition to hiatal hernias and acid reflux. 
10.1.3 Limitations 
The first limitation in this section of the replication study was the conclusive definition of 
BE. All BE patients recruited as part of the ChOPIN clinical trial had to meet the strict 
Prague criteria with measurements of C1M1 or C0M2 (as detailed in section 8.1.1). It is 
possible that mistakes could have been made when recording these figures. In order to 
minimise potential errors, the CI (Professor Janusz Jankowski) checked all patient 
history forms, endoscopy reports and histology reports to ensure that all patients had a 
confirmed diagnosis of BE and the correct measurements were taken. Secondly, the 
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lack of conclusive expression data meant that possible gene targets could not be 
confidently identified.  
10.2 ANALYSIS OF SNPS IN EAC CASES 
Analysis of the four BE-associated SNPs rs3072 (chr2p24), rs9257809 (chr6p21) [2], 
rs2701108 (chr12q24) and rs9936833 (chr16q24) [2] in a small EAC sample set, 
showed no association (P>0.05) when comparing EAC cases to controls (Pmeta=0.18, 
0.57, 0.34 and 0.08 respectively). Two SNPs (rs9257809 and rs2701108) were 
significant (P<0.05) when comparing BE to EAC cases (Pmeta=0.03 and 0.02 
respectively), suggesting their involvement is associated with BE rather than EAC. 
However, there are limitations attached to this analysis. Firstly, the number of cases 
used is considerably small when analysing genome-wide significant BE SNPs in a 
separate disease (EAC) sample set (305 UK and 176 Dutch). Secondly, there is no 
guarantee that all EAC cases analysed did not also have BE, either before or as well 
as the presence of EAC, as BE can be asymptomatic. Therefore they may not have 
been true EAC-only cases. In order to improve upon this further, more EAC cases who 
have been under endoscopic surveillance and are known not to have had, or have, BE 
need to be analysed. 
10.3 REPLICATION OF LEVINE ET AL (2013) [3] SNPS 
10.3.1 Four BE/EAC-associated SNPs 
Our replication of the four BE/EAC-associated SNPs reported in Levine et al (2013) [3] 
showed support for two SNPs (rs2687201 and rs10423674) and limited support for a 
third SNP (rs11889015). However, one of two genome-wide significant SNPs in 
CRTC1 (rs10419226) was not supported. Interestingly, the SNP not supported in our 
data was the strongest association in the Levine et al (2013) [3] study. We also found 
rs2687201, near FOXP1 to be genome-wide significance in a BE-only meta-analysis 
(P=4.61×10−8, OR=1.16, 95%CI=1.10-1.23). FOXP1 is a transcription factor important 
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in the regulation of oesophageal muscle development as described by Shu et al (2007) 
[172]. 
The limitations here were the number of cohorts each SNP was analysed in, and hence 
the total sample size. Three SNPs were analysed in three cohorts (Levine Discovery, 
Levine Replication and our Discovery), whilst one (the other SNP near CRTC1) was 
additionally genotyped in two extra cohorts (UKREP1 and Dutch). This could account 
for the support of one of the CRTC1 SNPs (number of studies=5) and not the other 
(number of studies=3), as the likelihood of detecting the effect is reduced due to 
decreased statistical power. Another limitation was the different genotyping methods; 
imputation of three SNPs and direct genotyping of one SNP, although all three imputed 
SNPs had an info score >0.95. 
10.3.2 Analysis of Four Selected SNPs from Levine et al (2013) [3] 
All four SNPs selected were supported in our study with regards to direction of effect, 
however the P values were not significant in our study alone. In a BE-only meta-
analysis of the Levine et al (2013) [3] study and this study, two out of four SNPs 
showed association improvement, suggesting limited association with disease; but 
none reached genome-wide significance. Upon meta-analysis of the Levine et al (2013) 
[3] BE/EAC data and our BE data (hence increasing statistical power), three of the four 
SNPs showed improvement in their association, suggesting limited disease association; 
with rs3784262 (located near ALDH1A2), reaching genome-wide significance; 
Pmeta=3.72×10−9, OR=0.90, 95%CI 0.87-0.93. Aldehyde dehydrogenase 1 family, 
member A2 (ALDH1A2) encodes an enzyme that catalyzes the synthesis of retinoic 
acid (RA) from retinaldehyde. It is thought to be involved in many cellular processes, 
including alcohol metabolism [173], where a recent study has identified methylation of 
a CpG site near this gene to be associated with loss of control over drinking [174]. This 
gene has also been implicated in TOF syndrome (similar to TBX5) [175] and is a 
candidate tumour suppressor gene in prostate cancer [176].  
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The limitation in this section of the study was the sample size in which the SNPs were 
genotyped. Meta-analysis was performed on all SNPs once they were genotyped in 6 
cohorts. One SNP (rs3784262) was then genotyped in a further 3 cohorts, due to the P 
value nearing the significance threshold. In order to gain a clear overview of the 
disease association of each SNP, all should have been genotyped in the same number 
of cohorts, so that the statistical power of all SNPs analysed was the same. 
10.4 FUTURE RESEARCH 
The following research needs to be fulfilled in order to gain a greater understanding of 
the disease:  
1. To genotype rs1920562 (the imputed SNP at 12q24 found to be more 
statistically significant (PDiscovery=1.4×10−5, OR=1.19) than the lead genotyped 
SNP rs2701108 (PDiscovery=1.4×10−3, OR=1.14)) in all replication samples. To 
then determine, with the same statistical power, which SNP (rs2701108 or 
rs1920562) is highly associated with BE.  
2. To obtain and analyse a greater number of pure EAC-only cases, increasing 
statistical power, for SNP association testing. 
3. To ensure that statistical power is the same throughout, there is a need to 
genotype and analyse seven Levine et al (2013) [3] SNPs (the four BE/EAC 
associated SNPs and three of the four selected for replication) in the same 
number of our BE-only samples (as was done for rs3784262). 
10.5 OVERVIEW 
The information generated from the Levine et al (2013) [3] BE/EAC GWAS, the Su et al 
(2012) [2] BE GWAS and the Palles et al (2015) [1] BE Replication study allows the 
generation of hypotheses regarding the potential processes involved in BE. Firstly, 
transcription factors appear to play an important role, particularly those involved in 
development and structure of the thorax, diaphragm and oesophagus. The SNPs near 
FOXF1 [2], FOXP1 [3], BARX1 [3], GDF7 [1] and TBX5 [1] support this hypothesis. 
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Secondly, the inflammatory response may play an important role, a theory supported 
by the SNP located within the HLA region [2]. Theoretically, the two groups of SNPs 
together could influence the development BE via the onset of GERD, perhaps through 
diaphragmatic structure (hiatal hernias), leading to an inflammatory response to the 
refluxed gastric acid within the oesophagus. Clinical trials provide an important source 
of information and sample collection for disease research. Trials investigating drug 
therapy also provide insight into the possible disease mechanisms; we therefore await 
with interest the outcome of clinical trials such as AspECT.  
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11. APPENDICES 
Figure 11.1: Patient History Form from the ChOPIN clinical trial protocol (Version 
6). 
 
PLEASE COMPLETE ALL SECTIONS  
(To avoid duplication in entering the data for Participants in both BOSS and ChOPIN, please attach BOSS 
INITIAL HISTORY SHEET and complete any additional information required on this form) 
Inclusion criteria – please tick box to confirm the met criteria 
Aged 18 or over  
Patient/subject or legal representative is willing and able to give informed consent for participation in the study  
With any one or combination of the following (please tick all that apply): 
! Endoscopically diagnosed with reflux oesophagitis, grade C or D according to Los Angeles Reflux criteria  
— endoscopy report required (and histology if available) from within 2 years of recruitment  
! Endoscopically and histologically diagnosed Barrett’s oesophagus of C1M1 or C0M2 or greater  
(by Prague C&M criteria, circumferential Barrett’s 1cm or greater or a 2cm or greater tongue of Barrett’s) 
— endoscopy and histology reports required from within 2 years of recruitment  
! Histologically proven low or high grade dysplasia in Barrett’s oesophagus 
— endoscopy and histology reports required from within 2 years of recruitment  
! Histologically proven oesophageal cancer 
— histology report confirming diagnosis required (and endoscopy report if available)  
 
SECTION 1 
 
PATIENT DETAILS 
 
Gender:  M  F  Weight  Kg Height   cm 
ChOPIN Investigator Reported Patient History Form 
 
To be completed for all patients willing to participate in ChOPIN 
REC REFERENCE: 06/Q1603/07 
Site: Investigator: 
Study Number: ChP  Pt Initials:    First | Mid | Last Date of birth:   dd  | mon | yyyy 
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Ethnicity:  
(a) WHITE 
1 British 
1 Irish 
 
1 Any other White background 
 please write in below 
 ……………………………… 
(b) (BLACK or BLACK BRITISH) 
1 Caribbean 
1 African 
 
1 Any other Black background 
 please write in below 
 ……………………………. 
(c) ASIAN or ASIAN BRITISH 
1 Indian 
1 Pakistani 
1 Bangladeshi 
1 Any other Asian background 
 please write in below 
 …………………………….. 
(d) MIXED 
1 White and Black Caribbean 
1 White and Black African 
1 White and Asian 
1 Any other Mixed background 
 please write in below 
 ……………………………… 
(e) CHINESE or OTHER ETHNIC 
GROUP 
1 Chinese 
1 Any other Mixed background 
 please write in opposite 
 
1 Patient refusal 
 
 
SECTION 2 
 
ALCOHOL INTAKE  
 
Yes       No   
 
If yes, please specify amount/week:                units    
 
SMOKING HISTORY 
 
current smoker      previous smoker  never smoked   
 
For current and previous smokers   
Years of smoking: ………………….  Number per day: ………………… 
 
BARRETT’S HISTORY  
 
Duration of reflux symptoms:                                                                                       Year(s) 
 
Date of endoscopy confirming Barrett’s oesophagus                Date :  dd | Mon | yyyy     
 
Date of most recent endoscopy if different from above             Date :  dd | Mon | yyyy    
 
Regular surveillance for Barretts oesophagus prior to trial entry     No            Yes         
 
 
ENDOSCOPY FINDINGS AT STUDY ENTRY (OR WITHIN 2 YEARS) 
 
Length of circumferential Columnar Lining                     C       .      cm (Barrett;’s 
only) 
 
Length of Tongues of Columnar Lining (maximal extent)                                   M       .      cm (Barrett’s 
only) 
 
Was a hiatal hernia present?   No   Yes  Size:................................................ 
Was intestinal metaplasia present?  No   Yes  
Was indefinite dysplasia present?   No   Yes  
Was low grade dysplasia present?   No   Yes  
Was high grade dysplasia present?   No   Yes  
Mucosal break(s) / Oesophagitis  No                 Yes  
               (if yes - Los Angeles Classification grade  A   B   C   D  ) 
Please calculate amount of pure alcohol consumed per 
week, using the conversion table below 
1 pt of beer 2 units 
Spirit (25 ml) 1 unit 
Spirit (35 ml) 1.5 units 
Glass of wine (125 ml) 1.5 units 
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Was oesophageal adenocarcinoma present?    No              Yes  
Was oesophageal squamous cell cancer present?     No               Yes  
Was oesophageal poorly differentiated epithelial malignancy present?    No              Yes  
Was a junctional tumour present?      No     Yes-Siewert type I type II  
 
 
HELICOBACTER TEST 
Not taken     If taken, was the result:  Positive    
Positive and Eradicated  
     Negative    
     Not known   
 
DOCUMENTED HISTORY OF VASCULAR DISEASE 
Does the patient have a history of any of the following (please tick):  No  Yes
  
Myocardial infarction:          
Angina (physician diagnosed):          
Coronary intervention (e.g. prior bypass surgery, coronary angioplasty or stent):     
Carotid artery stenosis on ultrasound or angiography:       
Cerebrovascular accident:          
Transient ischaemic attack:          
Peripheral vascular disease (e.g. history of claudication, prior peripheral vascular disease):    
Diabetes mellitus:           
Hypertension:           
Hyperlipidaemia and high cholesterol          
(LDL >130 mg/dl (or >3.4 mmol/L) and/or HDL <40 mg/dl (or <1.0mmol/L)):     
 
SECTION 3 
 
FAMILY HISTORY-digestive tract related conditions only   No   Yes       
(please give details, below) 
  
Relation to patient 
(brother, sister, 
parent,  or child) 
Heartburn Barrett’s Age at 
diagnosis 
Oesophageal Cancer 
(type) 
Age at 
diagnosis 
      
      
      
 
UPPER GI SURGERY 
Previous upper gastrointestinal surgery:        No                           Yes    (please give details, below) 
 
 
 
 
CURRENT 
MEDICATIO
N- digestive 
tract related medication and long term (≥ 3 months) NSAID/ aspirin use only 
 
Drug (brand name) Dosage 
Dose 
(Including 
units) 
 
Frequency 
Route 
e.g. IV 
Form 
e.g. 
tablet 
Indication  
Start Date 
      Mon | yyyy    
      Mon | yyyy    
      Mon | yyyy    
Type of Surgery 
 
Date of Surgery Outcome 
 Mon | yyyy     
 Mon | yyyy     
 Mon | yyyy     
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      Mon | yyyy    
      Mon | yyyy    
 
FORM COMPLETED BY: ________________________________     (print name)  
 
SIGNATURE __________________________________    Date: DD | MON | YYYY 
 
Site: Hospital name  
Investigator: The consultant responsible for the care of the patient.  
Trial number: This is the unique number that identifies this patient in the ChOPIN study pre-determined at the ChOPIN 
study office and will be supplied to the trial site 
Date of Birth: The patient’s date of birth must be written in the following format dd/mon/yyyy, e.g. 01/FEB/1977.  
Pt Initials: Record the patient’s first, middle and last initial in the spaces provided. If the patient has no middle initial, 
please record a dash  
Completed by Print name clearly, sign and provide the date when the form is completed in the correct format (see 
above). 
 
Please return the completed form together with endoscopy and pathology report forms (participant identifiable 
information deleted) to: 
 
ChOPIN study Office 
The John Bull Building 
Plymouth University Peninsula School of Medicine and Dentistry 
Tamar Science Park 
Plymouth 
Devon, PL6 8BU 
 
Tel Number:    01752 437402 
Fax Number:   01752 517842 
 
Forms must be completed in black ball-point pen 
Cross out errors with a single stroke, insert the correction and initial & date the change. 
Correction fluid and /or sticky labels must not be use 
Figure 1: Siewert Classification (for adenocarcinoma of the oesophagogastric junction (AEG)
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5 
rs6926118 
 
6 
 
3320615 
 
N
O
 
 
* 
 
discovery P
<1×10
−4, 
not on im
m
unochip 
 
0.98 (0.82-1.14) 
 
0.816 
 
0.86 (0.76-0.95) 
 
1.30×10
−3 
 
3 
rs7042370 
 
9 
 
12775073 
 
Y
E
S
 
 
0.999 
 
discovery P
<1×10
−4, 
not on im
m
unochip 
 
1.03 (0.93-1.12) 
 
0.619 
 
0.90 (0.84-0.96) 
 
4.84×10
−4 
 
2 
rs4858738 
 
3 
 
19826462 
 
Y
E
S
 
 
0.998 
 
discovery P
<1×10
−4, 
not on im
m
unochip 
 
1.04 (0.93-1.15) 
 
0.501 
 
0.88 (0.81-0.95) 
 
2.55×10
−4 
 
2 
rs1935671 
  
20 
  
8331096 
  
Y
E
S
 
  
0.863 
  
m
eta P
<1×10
−4 
  
1.00 (0.89-1.10) 
  
0.935 
  
1.10 (1.04-1.16) 
  
8.66×10
−4 
  
4 
rs2902637 
 
10 
 
1.06E
+08 
 
N
O
 
 
* 
 
m
eta P
<1×10
−4 
 
1.01 (0.90-1.11) 
 
0.905 
 
1.10 (1.05-1.16) 
 
5.71×10
−4 
 
5 
rs10903038 
 
1 
 
24363645 
 
Y
E
S
 
 
0.999 
 
discovery P
<1×10
−4, 
not on im
m
unochip 
 
0.98 (0.87-1.08) 
 
0.656 
 
1.12 (1.05-1.18) 
 
7.36×10
−4 
 
2 
rs851727 
 
7 
 
1.47E
+08 
 
Y
E
S
 
 
1 
 
m
eta P
<1×10
−4 
 
1.09 (0.87-1.30) 
 
0.444 
 
0.85 (0.74-0.96) 
 
2.76×10
−3 
 
5 
rs9379897 
 
6 
 
26709505 
 
Y
E
S
 
 
1 
 
m
eta P
<1×10
−4 
 
0.86 (0.73-0.99) 
 
0.022 
 
0.86 (0.79-0.92) 
 
7.69×10
−6 
 
5 
  
 
115 x 
rs9524596 
 
13 
 
94166840 
 
Y
E
S
 
 
0.999 
 
m
eta P
<1×10
−4 
 
0.94 (0.85-1.03) 
 
0.156 
 
0.91 (0.86-0.96) 
 
5.69×10
−5 
 
5 
rs6903535 
 
6 
 
28525201 
 
Y
E
S
 
 
0.999 
 
m
eta P
<1×10
−4 
 
0.98 (0.89-1.08) 
 
0.731 
 
0.92 (0.87-0.97) 
 
5.42×10
−4 
 
5 
rs6903130 
  
6 
  
32840188 
  
N
O
 
  
N
A
 
  
m
eta P
<1×10
−4 
  
  
  
  
  
  
  
  
  
  
rs292808 
  
1 
  
33819233 
  
N
O
 
  
N
A
 
  
P
<1×10
−4 in sex-
differentiated analysis 
of discovery 
  
  
  
  
  
  
  
  
  
  
rs10210285 
 
2 
 
1.43E
+08 
 
Y
E
S
 
 
0.998 
 
P
<1×10
−4 in sex-
differentiated analysis 
of discovery 
 
1.06 (0.87-1.25) 
 
0.538 
 
1.14 (1.02-1.26) 
 
3.08×10
−2 
 
2 
rs7609738 
 
3 
 
1.83E
+08 
 
Y
E
S
 
 
0.999 
 
P
<1×10
−4 in sex-
differentiated analysis 
of discovery 
 
1.06 (0.96-1.16) 
 
0.251 
 
1.05 (0.99-1.11) 
 
9.39×10
−2 
 
2 
rs7816766 
 
8 
 
4523552 
 
Y
E
S
 
 
0.991 
 
P
<1×10
−4 in sex-
differentiated analysis 
of discovery 
 
0.88 (0.78-0.97) 
 
0.008 
 
1.12 (1.06-1.18) 
 
2.48×10
−4 
 
2 
rs719527 
 
11 
 
1.03E
+08 
 
Y
E
S
 
 
0.998 
 
P
<1×10
−4 in sex-
differentiated analysis 
of discovery 
 
0.99 (0.88-1.10) 
 
0.872 
 
1.08 (1.01-1.15) 
 
2.33×10
−2 
 
2 
rs2715425 
 
15 
 
97278619 
 
Y
E
S
 
 
0.998 
 
IG
F1R
 candidate 
variant 
 
0.97 (0.86-1.09) 
 
0.647 
 
0.97 (0.86-1.09) 
 
0.647 
 
1 
rs6898743 
 
5 
 
42638249 
 
Y
E
S
 
 
0.999 
 
G
H
R
 candidate variant 
 
1.03 (0.91-1.15) 
 
0.611 
 
1.03 (0.91-1.15) 
 
0.611 
 
1 
rs1325190 
 
1 
 
1.98E
+08 
 
Y
E
S
 
 
1 
 
m
eta P
<1×10
−4 
 
1.05 (0.95-1.15) 
 
0.369 
 
0.92 (0.87-0.97) 
 
1.82×10
−3 
 
5 
  
 
116 x 
rs7255 
  
2 
  
20742301 
  
Y
E
S
 
  
0.901 
  
m
eta P
<1×10
−4 
  
0.87 (0.78-0.96) 
  
0.003 
  
0.87 (0.83-0.92) 
  
1.09×10
−8 
  
5 
rs13385191 
 
2 
 
20751746 
 
Y
E
S
 
 
0.999 
 
m
eta P
<1×10
−4 
 
1.05 (0.94-1.15) 
 
0.375 
 
1.11 (1.06-1.17) 
 
1.06×10
−4 
 
5 
rs340620 
 
2 
 
20787591 
 
Y
E
S
 
 
0.982 
 
m
eta P
<1×10
−4 
 
0.94 (0.84-1.03) 
 
0.175 
 
0.90 (0.85-0.95) 
 
1.52×10
−5 
 
5 
rs6727683 
  
2 
  
35429477 
  
N
O
 
  
N
A
 
  
m
eta P
<1×10
−4 
  
  
  
  
  
  
  
  
  
  
rs12993283 
 
2 
 
35445909 
 
Y
E
S
 
 
0.999 
 
m
eta P
<1×10
−4 
 
0.93 (0.84-1.02) 
 
0.121 
 
0.89 (0.84-0.93) 
 
2.15×10
−7 
 
5 
rs819848 
 
3 
 
1.57E
+08 
 
Y
E
S
 
 
0.994 
 
m
eta P
<1×10
−4 
 
1.02 (0.92-1.11) 
 
0.755 
 
1.10 (1.05-1.15) 
 
3.75×10
−4 
 
5 
rs9824398 
 
3 
 
1.88E
+08 
 
Y
E
S
 
 
1 
 
m
eta P
<1×10
−4 
 
1.06 (0.97-1.15) 
 
0.241 
 
1.10 (1.05-1.15) 
 
5.65×10
−5 
 
5 
rs9879899 
 
3 
 
1.88E
+08 
 
Y
E
S
 
 
0.993 
 
m
eta P
<1×10
−4 
 
0.95 (0.86-1.05) 
 
0.321 
 
0.91 (0.86-0.96) 
 
6.59×10
−5 
 
5 
rs13157599 
 
5 
 
1.23E
+08 
 
Y
E
S
 
 
1 
 
m
eta P
<1×10
−4 
 
0.92 (0.72-1.13) 
 
0.461 
 
1.19 (1.08-1.29) 
 
1.43×10
−3 
 
5 
rs35936561 
 
7 
 
1.56E
+08 
 
Y
E
S
 
 
0.998 
 
m
eta P
<1×10
−4 
 
0.98 (0.86-1.09) 
 
0.682 
 
0.91 (0.86-0.96) 
 
1.01×10
−4 
 
5 
rs7836059 
  
8 
  
11309574 
  
N
O
 
  
N
A
 
  
m
eta P
<1×10
−4 
  
  
  
  
  
  
  
  
  
  
rs2898290 
 
8 
 
11471318 
 
Y
E
S
 
 
0.989 
 
m
eta P
<1×10
−4 
 
0.92 (0.83-1.01) 
 
0.083 
 
0.90 (0.86-0.95) 
 
1.42×10
−5 
 
5 
rs12677326 
  
8 
  
11476634 
  
N
O
 
  
N
A
 
  
m
eta P
<1×10
−4 
  
  
  
  
  
  
  
  
  
  
rs13267835 
 
8 
 
11542328 
 
Y
E
S
 
 
0.998 
 
m
eta P
<1×10
−4 
 
0.97 (0.83-1.10) 
 
0.615 
 
0.87 (0.80-0.94) 
 
9.11×10
−5 
 
5 
rs13273672 
 
8 
 
11649790 
 
Y
E
S
 
 
0.999 
 
m
eta P
<1×10
−4 
 
0.98 (0.89-1.08) 
 
0.739 
 
1.09 (1.04-1.14) 
 
6.90×10
−4 
 
5 
  
 
117 x 
rs8180912 
 
8 
 
11677400 
 
Y
E
S
 
 
0.999 
 
m
eta P
<1×10
−4 
 
1.00 (0.89-1.12) 
 
0.988 
 
0.90 (0.84-0.96) 
 
3.73×10
−4 
 
5 
rs7895043 
 
10 
 
71016742 
 
Y
E
S
 
 
0.999 
 
m
eta P
<1×10
−4 
 
1.04 (0.95-1.13) 
 
0.428 
 
1.09 (1.05-1.14) 
 
1.52×10
−4 
 
5 
rs1265496 
  
12 
  
1.13E
+08 
  
N
O
 
  
N
A
 
  
m
eta P
<1×10
−4 
  
  
  
  
  
  
  
  
  
  
rs12903220 
  
15 
  
59040471 
  
N
O
 
  
N
A
 
  
m
eta P
<1×10
−4 
  
  
  
  
  
  
  
  
  
  
rs7168393 
 
15 
 
95353461 
 
Y
E
S
 
 
0.999 
 
m
eta P
<1×10
−4 
 
1.01 (0.85-1.17) 
 
0.866 
 
1.14 (1.07-1.21) 
 
1.96×10
−4 
 
5 
rs7173314 
  
15 
  
95353711 
  
N
O
 
  
N
A
 
  
m
eta P
<1×10
−4 
  
  
  
  
  
  
  
  
  
  
rs2535483 
  
15 
  
95357916 
  
N
O
 
  
N
A
 
  
m
eta P
<1×10
−4 
  
  
  
  
  
  
  
  
  
  
rs9941024 
 
16 
 
5734313 
 
Y
E
S
 
 
1 
 
m
eta P
<1×10
−4 
 
0.90 (0.81-0.99) 
 
0.03 
 
0.89 (0.84-0.94) 
 
6.72×10
−7 
 
5 
rs7200175 
  
16 
  
5742063 
  
N
O
 
  
N
A
 
  
m
eta P
<1×10
−4 
  
  
  
  
  
  
  
  
  
  
rs11866983 
 
16 
 
5743925 
 
Y
E
S
 
 
0.997 
 
m
eta P
<1×10
−4 
 
1.09 (0.99-1.19) 
 
0.088 
 
1.12 (1.07-1.17) 
 
4.93×10
−6 
 
5 
rs9936833 
 
16 
 
84960619 
 
Y
E
S
 
 
0.997 
 
m
eta P
<1×10
−4 
 
1.02 (0.91-1.14) 
 
0.669 
 
1.15 (1.1-1.20) 
 
4.68×10
−8 
 
5 
rs1532167 
  
16 
  
84961705 
  
N
O
 
  
N
A
 
  
m
eta P
<1×10
−4 
  
  
  
  
  
  
  
  
  
  
rs7187365 
  
16 
  
85069416 
  
N
O
 
  
N
A
 
  
m
eta P
<1×10
−4 
  
  
  
  
  
  
  
  
  
  
rs889592 
 
16 
 
85076757 
 
Y
E
S
 
 
1 
 
m
eta P
<1×10
−4 
 
0.99 (0.87-1.11) 
 
0.921 
 
0.90 (0.83-0.96) 
 
3.00×10
−4 
 
5 
rs4792827 
  
17 
  
41487141 
  
N
O
 
  
N
A
 
  
m
eta P
<1×10
−4 
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Table 11.1: SN
Ps prioritised for further genotyping in R
eplication Phase 2 sam
ples (Irish cohort of 245 cases and 473 controls and a U
K
 cohort of 1,765 cases and 1,586 
controls) listed in order of priority, based on D
iscovery and R
eplication Phase 1 m
eta P value. *S
N
P
s in top 40 that couldn’t be genotyped by sequenom
 w
ere genotyped by 
K
A
S
P
ar.  K
A
S
P
ar call rates w
ere all > 95%
. S
N
P
s highlighted in grey w
ere excluded because of call rates<95%
, S
N
P
s highlighted in blue failed at the design stage of the iP
LE
X
. 
S
N
P
s w
ere selected based on the follow
ing criteria: (i) m
eta P
<10
−4 = P
association <10
−4 in com
bined D
iscovery and R
eplication P
hase 1 analysis, as described in S
u et al (2012) [2] 
(N
=63); (ii) discovery P
<10
−4, not on im
m
unochip = P
association <10
−4 in D
iscovery P
hase, but not included in the Im
m
unochip content (N
=12); (iii) P
<10
−4 in sex-differentiated analysis of 
discovery  =P
association <1 x 10
−4 in a sex-stratified analysis of the D
iscovery phase (N
=5); (iv) candidate variant = candidate polym
orphism
s that had previously been reported to be 
associated w
ith B
E
 and w
ere not w
ell tagged by the D
iscovery P
hase or Im
m
unochip arrays. N
ote that rs41341748 w
as also typed in U
K
 R
eplication P
hase 3 (O
R
=1.07, 95%
C
I 0.70-
1.43, P
m
eta =0.79). P
hase 2 M
eta consisted of Irish and U
K
R
E
P
2 sam
ples. D
iscovery + P
hases 1 &
 2 M
eta consisted of D
iscovery, U
K
R
E
P
1, D
utch R
eplication, U
K
R
E
P
2 and Irish 
sam
ples. N
ote that the D
utch R
eplication did not include the D
utch E
xtension at this stage (the D
utch E
xtension w
as only genotyped for the 7 S
N
P
s taken through to R
eplication P
hase 
3). C
hr, C
hrom
osom
e; O
R
, O
dds R
atio; P
, P
-value. 
rs6040146 
  
20 
  
10701237 
  
N
O
 
  
N
A
 
  
m
eta P
<1×10
−4 
  
  
  
  
  
  
  
  
  
  
  
 
119 x 
                            Table 11.2: Prim
ers used for the seven SN
Ps taken through to U
K
R
EP3. G
reen indicates prim
er used after optim
ization 
SN
P 
 
Prim
er 
 
Sequence 5'-3' 
 
N
 PC
R
 C
ycles 
rs3072 
 
A
llele A
 
 
G
A
A
G
G
TG
A
C
C
A
A
G
TTC
A
TG
C
TC
G
TTTC
C
TTA
A
A
A
TC
A
C
A
G
TA
C
TG
G
A
 
 
36 
 
A
llele G
 
 
G
A
A
G
G
TG
A
C
C
A
A
G
TTC
A
TG
C
TC
G
TTTC
C
TTA
A
A
A
TC
A
C
A
G
TA
C
TG
G
G
 
 
 
C
om
m
on 1 
 
A
TG
A
C
G
A
G
TG
G
C
TG
C
A
G
C
TTA
G
A
A
A
 
 
 
C
om
m
on 2 
 
TG
G
C
TG
C
A
G
C
TTA
G
A
A
A
G
C
A
A
A
TTTC
A
T 
 
rs6751791 
 
A
llele A
 
 
G
A
A
G
G
TG
A
C
C
A
A
G
TTC
A
TG
C
TC
A
A
TG
G
A
G
TA
A
A
TTG
C
TA
G
C
A
A
A
C
TC
A
A
 
 
26 
 
A
llele G
 
 
G
A
A
G
G
TC
G
G
A
G
TC
A
A
C
G
G
A
TTA
A
TG
G
A
G
TA
A
A
TTG
C
TA
G
C
A
A
A
C
TC
A
G
 
 
 
C
om
m
on 1 
 
TTG
G
A
G
C
TC
TC
A
G
A
TTTTA
A
TC
C
TG
C
T 
 
 
C
om
m
on 2 
 
G
A
A
C
TG
C
G
TTG
G
A
G
C
TC
TC
A
G
A
TTT 
 
rs2731672 
 
A
llele A
 
 
G
A
A
G
G
TG
A
C
C
A
A
G
TTC
A
TG
C
TC
C
A
G
G
C
TC
A
TTTG
TTA
G
G
A
A
TG
TG
A
 
 
26 
 
A
llele G
 
 
G
A
A
G
G
TC
G
G
A
G
TC
A
A
C
G
G
A
TTC
A
G
G
C
TC
A
TTTG
TTA
G
G
A
A
TG
TG
G
 
 
 
C
om
m
on 1 
 
G
G
A
A
TTA
TA
A
A
G
C
TA
G
A
G
G
C
C
TTC
TC
TTT 
 
 
C
om
m
on 2 
 
A
G
G
C
C
TTC
TC
TTTC
C
A
TG
G
A
G
G
TT 
 
rs2701108 
 
A
llele A
 
 
G
A
A
G
G
TG
A
C
C
A
A
G
TTC
A
TG
C
TG
G
C
A
G
G
A
G
A
A
A
A
TG
TG
TA
C
TC
TC
A
T 
 
26 
 
A
llele G
 
 
G
A
A
G
G
TC
G
G
A
G
TC
A
A
C
G
G
A
TTG
C
A
G
G
A
G
A
A
A
A
TG
TG
TA
C
TC
TC
A
C
 
 
 
C
om
m
on 1 
 
C
C
TC
C
C
TG
C
C
C
TG
C
C
TC
C
TA
 
 
 
C
om
m
on 2 
 
C
TG
C
C
TC
C
TA
G
G
TG
A
C
TC
TG
G
A
A
 
 
rs189247 
 
A
llele A
 
 
G
A
A
G
G
TG
A
C
C
A
A
G
TTC
A
TG
C
TC
A
G
A
TG
C
C
C
A
TC
A
G
A
A
A
A
C
C
C
A
A
 
 
26 
 
A
llele G
 
 
G
A
A
G
G
TG
A
C
C
A
A
G
TTC
A
TG
C
TC
A
G
A
TG
C
C
C
A
TC
A
G
A
A
A
A
C
C
C
A
G
 
 
 
C
om
m
on 1 
 
C
C
TG
A
C
A
C
TC
C
A
C
A
G
A
TG
G
A
A
A
C
A
A
 
 
 
C
om
m
on 2 
 
C
A
G
A
TG
G
A
A
A
C
A
A
A
C
C
TG
G
G
A
A
C
C
TT 
 
rs2043633 
 
A
llele A
 
 
G
A
A
G
G
TC
G
G
A
G
TC
A
A
C
G
G
A
TTG
A
C
C
TTA
TTTG
G
A
G
A
C
A
G
G
G
TG
TT 
 
26 
 
A
llele C
 
 
G
A
A
G
G
TC
G
G
A
G
TC
A
A
C
G
G
A
TTG
A
C
C
TTA
TTTG
G
A
G
A
C
A
G
G
G
TG
TG
 
 
 
C
om
m
on 1 
 
C
C
A
C
C
C
TA
A
TG
A
C
C
TG
A
TTTTTA
C
TTG
A
T 
 
 
C
om
m
on 2 
 
TG
A
C
C
TG
A
TTTTTA
C
TTG
A
TTA
G
C
TC
C
A
TA
 
 
rs12985909 
 
A
llele A
 
 
G
A
A
G
G
TC
G
G
A
G
TC
A
A
C
G
G
A
TTG
G
TG
G
C
C
A
A
TC
A
G
C
G
TTC
C
T 
 
26 
 
A
llele G
 
 
G
A
A
G
G
TC
G
G
A
G
TC
A
A
C
G
G
A
TTG
G
TG
G
C
C
A
A
TC
A
G
C
G
TTC
C
C
 
 
 
C
om
m
on 1 
 
G
TG
C
TC
TTTC
TTTA
A
C
C
A
A
TC
C
C
TG
TA
 
 
 
C
om
m
on 2 
 
C
A
A
TC
C
C
TG
TA
G
C
C
A
G
G
G
G
G
A
T 
 
  
 
120 x 
              
Table 11.3: Prim
ers used for K
A
SP genotyping of the Levine SN
Ps. Four selected Levine et al (2013) [3] S
N
P
s taken through to replication phases and 
the one Levine et al (2013) [3] S
N
P
 (rs11771429) genotyped in our D
iscovery P
hase using K
A
S
P
ar. G
reen indicates prim
er used after optim
ization. 
SN
P 
 
Prim
er 
 
Sequence 5'-3' 
 
N
 PC
R
 C
ycles 
rs1497205 
 
A
llele A
 
 
G
A
A
G
G
TG
A
C
C
A
A
G
TTC
A
TG
C
TA
G
C
C
TA
TC
G
TC
C
C
TC
TG
G
TG
T 
 
26 
 
A
llele C
 
 
G
A
A
G
G
TC
G
G
A
G
TC
A
A
C
G
G
A
TTG
C
C
TA
TC
G
TC
C
C
TC
TG
G
TG
C
 
 
 
C
om
m
on 1 
 
C
C
A
TTA
TG
A
A
G
C
A
C
A
G
A
G
C
A
C
C
TG
A
 
 
 
C
om
m
on 2 
 
C
A
C
A
G
A
G
C
A
C
C
TG
A
G
C
C
TA
TA
A
A
C
A
A
 
 
rs254348 
  
A
llele A
 
  
G
A
A
G
G
TG
A
C
C
A
A
G
TTC
A
TG
C
TA
C
A
A
G
A
A
G
G
A
G
A
G
G
A
TA
A
G
G
A
G
A
C
A
 
  
36 
 
A
llele C
 
 
G
A
A
G
G
TC
G
G
A
G
TC
A
A
C
G
G
A
TTA
A
G
A
A
G
G
A
G
A
G
G
A
TA
A
G
G
A
G
A
C
G
 
 
 
C
om
m
on 1 
 
C
A
TG
A
G
G
G
TC
A
G
G
C
TG
G
G
G
A
A
T 
 
  
C
om
m
on 2 
  
C
A
G
G
C
TG
G
G
G
A
A
TG
A
C
A
G
A
G
G
A
T 
  
rs3784262 
 
A
llele A
 
 
G
A
A
G
G
TG
A
C
C
A
A
G
TTC
A
TG
C
TC
TG
A
G
C
A
C
A
TA
A
TC
TG
A
C
TG
G
C
A
T 
 
26 
 
A
llele G
 
 
G
A
A
G
G
TC
G
G
A
G
TC
A
A
C
G
G
A
TTG
A
G
C
A
C
A
TA
A
TC
TG
A
C
TG
G
C
A
C
 
 
 
C
om
m
on 1 
 
C
C
TC
TG
G
A
G
G
A
A
A
G
G
A
A
TTTA
A
A
A
A
TA
A
A
A
 
 
 
C
om
m
on 2 
 
C
A
A
TTTTTTC
C
TC
TG
G
A
G
G
A
A
A
G
G
A
A
TTTA
 
 
rs4523255 
  
A
llele C
 
  
G
A
A
G
G
TG
A
C
C
A
A
G
TTC
A
TG
C
TC
A
TG
A
A
TC
A
G
G
A
TTA
A
A
G
A
A
TC
TG
TG
G
 
  
36 
 
A
llele T 
 
G
A
A
G
G
TC
G
G
A
G
TC
A
A
C
G
G
A
TTC
A
TG
A
A
TC
A
G
G
A
TTA
A
A
G
A
A
TC
TG
TG
A
 
 
 
C
om
m
on 1 
 
A
C
TA
A
TG
TC
TC
C
A
TC
C
TG
C
A
C
A
A
TG
A
A
A
 
 
  
C
om
m
on 2 
  
C
C
A
TC
C
TG
C
A
C
A
A
TG
A
A
A
A
TG
A
A
C
G
TTA
T 
  
rs11771429 
  
A
llele C
 
  
G
A
A
G
G
TG
A
C
C
A
A
G
TTC
A
TG
C
TC
A
A
A
G
TTTA
TC
G
TA
A
A
A
C
TA
C
A
G
G
A
G
G
 
  
36 
 
A
llele T 
 
G
A
A
G
G
TC
G
G
A
G
TC
A
A
C
G
G
A
TTA
C
A
A
A
G
TTTA
TC
G
TA
A
A
A
C
TA
C
A
G
G
A
G
A
 
 
 
C
om
m
on 1 
 
A
A
A
G
C
C
A
A
A
G
G
G
C
C
TTG
A
TA
A
C
A
TTA
G
TT 
 
  
C
om
m
on 2 
  
G
G
G
C
C
TTG
A
TA
A
C
A
TTA
G
TTTG
G
A
A
G
A
TT 
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Table&11.4:&Cohort&breakdow
n&for&the&seven&selected&SN
Ps&taken&into&Replication&Phase&3.&*Alleles!show
n!as!m
inor/m
ajor.!All!results!are!presented!w
ith!respect!to!the!m
inor!allele.!
rs6751791!w
as!not!genotyped!in!BEACO
N
.!!Data!presented!are!for!a!proxy!SN
P:!rs7598399;!r 2=!1.!Also,!rs189247!w
as!not!genotyped!in!BEACO
N
,!but!w
as!im
puted!from
!4!genotyped!
SN
Ps!(rs991757,!rs2670927,!rs2670930!and!rs234540).!!Im
putation!accuracy!using!this!strategy!w
as!98.2%
,!confirm
ed!by!im
puting!sam
ples!for!w
hich!genotypes!from
!sequence!data!
w
ere!available!for!all!5!SN
Ps!and!checking!concordance!of!im
puted!and!sequenced!genotypes.!Dutch!cohort!consists!of!Dutch!Replication!(Phase!1!replication)!and!Dutch!Extension!!
(Phase!3!replication).!O
R=O
dds!Ratio,!95%
CI=95%
!Confidence!Intervals,!P=PZvalue.!
SN
P 
C
hr 
Position 
A
lleles
* 
Statistics 
U
K
 
D
iscovery 
D
utch 
U
K
R
EP1 
Irish 
U
K
R
EP2 
U
K
R
EP3 
B
elgian 
B
EA
C
O
N
 
M
eta-
analysis 
rs3072 
2 
20878406 
G
/A
 
O
R
 
1.23 
1.20 
1.06 
1.02 
1.15 
1.18 
0.95 
1.11 
1.14 
95%
C
I 
1.14-1.33 
1.05-1.38 
0.97-1.16 
0.81-1.30 
1.04-1.28 
1.04-1.34 
0.79-1.14 
1.03-1.19 
1.09-1.18 
P 
2.64x10
-7 
8.77x10
-3 
2.22x10
-1 
8.47x10
-1 
4.79x10
-3 
1.18x10
-2 
5.58x10
-1 
6.64x10
-3 
1.75×10
−11 
rs6751791 
2 
35581997 
A
/G
 
O
R
 
1.15 
1.10 
1.18 
1.30 
1.03 
0.98 
0.96 
1.00 
1.08 
95%
C
I 
1.06-1.23 
0.96-1.27 
1.08-1.29 
1.04-1.63 
0.93-1.13 
0.83-1.16 
0.80-1.14 
0.93-1.07 
1.04-1.12 
P 
5.03x10
-4 
1.51x10
-1 
3.05x10
-4 
2.22x10
-2 
5.97x10
-1 
8.04x10
-1 
6.29x10
-1 
8.92x10
-1 
7.65×10
−5 
rs2731672 
5 
176842474 
A
/G
 
O
R
 
1.18 
1.10 
1.15 
1.05 
1.10 
1.02 
0.90 
0.95 
1.07 
95%
C
I 
1.09-1.28 
0.94-1.29 
1.04-1.28 
0.82-1.35 
0.99-1.23 
0.85-1.24 
0.73-1.10 
0.88-1.03 
1.03-1.12 
P 
1.64x10
-4 
2.18x10
-1 
8.03x10
-3 
6.82x10
-1 
8.51x10
-2 
8.13x10
-1 
2.98x10
-1 
2.09x10
-1 
1.66x10
-3 
rs2701108 
12 
114674261 
G
/A
 
O
R
 
0.88 
0.91 
0.86 
0.71 
0.93 
0.97 
0.95 
0.91 
0.90 
95%
C
I 
0.81-0.95 
0.79-1.04 
0.78-0.94 
0.57-0.89 
0.84-1.03 
0.86-1.10 
0.80-1.14 
0.85-0.98 
0.86-0.93 
P 
1.00x10
-3 
1.62x10
-1 
9.76x10
-4 
2.86x10
-2 
1.46x10
-1 
6.69x10
-1 
6.04x10
-1 
1.43x10
-2 
7.48×10
−9 
rs189247 
15 
97586630 
A
/G
 
O
R
 
1.18 
1.23 
1.10 
1.03 
1.11 
1.07 
1.00 
1.04 
1.10 
95%
C
I 
1.09-1.27 
1.06-1.41 
1.00-1.21 
0.81-1.30 
1.00-1.23 
0.94-1.22 
0.84-1.19 
0.97-1.12 
1.06-1.14 
P 
5.67x10
-5 
5.00x10
-3 
4.36x10
-2 
8.21x10
-1 
4.02x10
-2 
2.80x10
-1 
9.89x10
-1 
3.10x10
-1 
3.55×10
−7 
rs2043633 
16 
5819274 
C
/A
 
O
R
 
0.85 
0.84 
0.90 
0.87 
0.88 
1.03 
0.84 
1.01 
0.92 
95%
C
I 
0.79-0.92 
0.74-0.97 
0.82-0.98 
0.70-1.09 
0.80-0.97 
0.90-1.17 
0.70-1.00 
0.94-1.09 
0.88-0.95 
P 
6.04x10
-5 
1.36x10
-2 
2.05x10
-2 
2.28x10
-1 
1.21x10
-2 
6.83x10
-1 
5.59x10
-2 
7.87x10
-1 
2.25×10
−6 
rs12985909 
19 
18439383 
G
/A
 
O
R
 
1.12 
1.14 
1.11 
1.09 
1.11 
1.03 
1.14 
1.07 
1.10 
95%
C
I 
1.04-1.21 
0.99-1.30 
1.02-1.22 
0.87-1.38 
1.01-1.22 
0.91-1.16 
0.95-1.37 
1.00-1.15 
1.06-1.14 
P 
2.94x10
-3 
6.06x10
-2 
1.87x10
-2 
4.44x10
-1 
3.80x10
-2 
6.47x10
-1 
1.51x10
-1 
5.20x10
-2 
3.28×10
−7 
  
 
122 x 
SN
P 
C
 
H
 
R
 
Position 
r 2 
R
EF/ 
A
LT 
A
llele 
EUR 
freq 
Location 
R
efseq genes 
G
 
E 
R
 
P 
Phast
C
ons 
Si-
Phy 
Proteins 
bound 
Prom
oter 
histone 
m
arks 
Enhancer 
histone 
m
arks 
D
N
ase 
eQ
TL 
tissues 
M
otifs 
changed 
rs9306894 
2 
20878105 
0.97 
A
/G
 
0.36 
intergenic 
G
D
F7(dist=6855), 
C
2orf43(dist=6713) 
  
  
  
  
  
G
M
12878 
N
H
D
F-
neo 
  
5 altered 
m
otifs 
rs9306895 
2 
20878153 
0.97 
T/C
 
0.36 
intergenic 
G
D
F7(dist=6903), 
C
2orf43(dist=6665) 
  
  
  
  
  
G
M
12878 
N
H
D
F-
neo 
  
H
M
G
-IY
, 
Lhx3, 
P
ou3f3 
rs3072 
2 
20878406 
1 
T/C
 
0.36 
intergenic 
G
D
F7(dist=7156), 
C
2orf43(dist=6412) 
  
  
  
  
  
G
M
12878 
  
  
G
A
TA
, 
G
fi1 
rs7255 
2 
20878820 
0.60 
T/C
 
0.53 
intergenic 
G
D
F7(dist=7570), 
C
2orf43(dist=5998) 
2.28 
S
core 
501; 
lod 
145 
  
  
  
G
M
12878 
  
  
G
ZF1, 
G
m
397, 
P
LZF 
rs10193919 
2 
20880833 
0.92 
C
/T 
0.35 
intergenic 
G
D
F7(dist=9583), 
C
2orf43(dist=3985) 
  
  
  
  
  
  
  
  
6 altered 
m
otifs 
rs2289081 
2 
20881840 
0.87 
G
/C
 
0.36 
intergenic 
G
D
F7(dist=10590), 
C
2orf43(dist=2978) 
  
  
  
  
  
  
  
  
4 altered 
m
otifs 
rs13394027 
2 
20882056 
0.50 
G
/A
 
0.23 
intergenic 
G
D
F7(dist=10806), 
C
2orf43(dist=2762) 
  
  
  
C
TC
F, 
R
A
D
21, 
S
M
C
3 
  
  
30 cell 
types 
4 eQ
TL 
tissues 
P
bx3 
rs10170771 
2 
20883216 
0.47 
T/C
 
0.25 
intergenic 
G
D
F7(dist=11966),  
C
2orf43(dist=1602) 
  
  
  
  
  
  
  
3 eQ
TL 
tissues 
4 altered 
m
otifs 
rs12622106 
2 
20883561 
0.47 
C
/T 
0.25 
intergenic 
G
D
F7(dist=12311), 
C
2orf43(dist=1257) 
  
  
  
C
JU
N
, 
JU
N
D
 
  
  
  
3 eQ
TL 
tissues 
  
rs10171934 
2 
20884546 
0.48 
A
/C
 
0.25 
dow
nstream
 
C
2orf43 
  
  
  
FO
X
A
1, 
P
300 
  
H
epG
2 
H
epG
2 
  
C
E
B
P
A
 
  
 
123 x 
Table 11.5:  Functional annotation of SN
Ps in LD
 (r 2>0.4) w
ith rs3072 using data from
 H
aploR
eg and A
N
N
O
VA
R
. Location, distance from
 R
efseq genes and G
E
R
P
, P
hastC
ons and 
S
iP
hy scores w
ere obtained through annovar. The follow
ing files w
ere dow
nloaded from
 annovar: hg19_refG
ene.txt, hg19_gerp++gt2.txt, hg19_phastC
onsE
lem
ents46w
ay.txt and ljb2_siphy.txt.  
A
ll S
N
P
s w
ith blank G
E
R
P
 scores m
ap to a location that score <2, therefore is regarded as not being evolutionarily conserved.  A
ll S
N
P
s w
ith blank P
hastcons scores represent S
N
P
s that do 
not m
ap to conserved regions.  N
one of the S
N
P
s scored according to S
iP
hy database (all blank). The H
um
an P
rotein A
tlas show
ed C
2orf43 to be expressed at m
oderate levels in norm
al 
squam
ous oesophageal epithelial cells and norm
al glandular stom
ach, but there w
as no expression data for the secreted protein G
D
F7. 
rs10182643 
2 
20884586 
0.48 
G
/C
 
0.25 
dow
nstream
 
C
2orf43 
  
  
  
FO
X
A
1, 
P
300, 
S
P
1 
  
H
epG
2 
H
epG
2 
3 eQ
TL 
tissues 
N
R
S
F, 
S
TA
T 
rs13385191 
2 
20888265 
0.46 
A
/G
 
0.25 
intronic 
C
2orf43 
2.86 
  
  
  
  
  
  
3 eQ
TL 
tissues 
E
sr2 
rs1437405 
2 
20929067 
0.42 
T/C
 
0.32 
intronic 
C
2orf43 
  
  
  
  
  
H
epG
2, 
H
uvec 
  
G
ibbs 
Frontal 
C
ortex 
22 
altered 
m
otifs 
rs2046325 
2 
20939706 
0.41 
T/C
 
0.32 
intronic 
C
2orf43 
  
  
  
  
  
  
  
  
12 
altered 
m
otifs 
  
 
124 x 
SN
P 
C
 
H
 
R
 
Position 
r 2 
R
EF/ 
A
LT 
A
llele 
EU
R
 
freq 
Location 
R
efseq genes 
G
 
E 
R
 
P 
Phast 
C
ons 
Si-
Phy 
Proteins 
bound 
Prom
oter 
histone 
m
arks 
Enhancer 
histone 
m
arks 
D
N
A
se 
eQ
TL 
tissues 
M
otifs 
changed 
rs1920562 
12 
114660658 
0.62 
T/C
 
0.35 
intergenic 
R
B
M
19(dist=256482), 
TB
X
5(dist=131077) 
  
S
core
556; 
lod 
243 
  
  
  
H
1, N
H
LF 
  
  
5 altered 
m
otifs 
rs12828548 
12 
114661066 
0.62 
C
/G
 
0.35 
intergenic 
R
B
M
19(dist=256890), 
TB
X
5(dist=130669) 
2.1 
  
  
  
  
H
1 
  
  
Foxj1, 
R
ad21, 
Zfp105 
rs11066998 
12 
114661789 
0.6 
A
/T 
0.35 
intergenic 
R
B
M
19(dist=257613), 
TB
X
5(dist=129946) 
  
  
  
  
  
  
  
  
B
ach2 
rs2555009 
12 
114666099 
0.51 
A
/G
 
0.52 
intergenic 
R
B
M
19(dist=261923), 
TB
X
5(dist=125636) 
  
  
  
  
  
H
epG
2 
  
  
  
rs11067002 
12 
114667046 
0.83 
T/A
 
0.34 
intergenic 
R
B
M
19(dist=262870), 
TB
X
5(dist=124689) 
  
  
  
  
  
  
  
  
C
IZ,  
E
vi-1 
rs2555019 
12 
114668618 
0.52 
T/C
 
0.52 
intergenic 
R
B
M
19(dist=264442), 
TB
X
5(dist=123117) 
2.13 
  
  
  
  
  
  
  
4 altered 
m
otifs 
rs1920568 
12 
114669732 
0.58 
G
/C
 
0.49 
intergenic 
R
B
M
19(dist=265556), 
TB
X
5(dist=122003) 
2.29 
  
  
  
  
  
  
  
E
W
S
R
1F
LI1, E
ts, 
S
TA
T 
rs2555016 
12 
114670663 
0.52 
T/G
 
0.52 
intergenic 
R
B
M
19(dist=266487), 
TB
X
5(dist=121072) 
  
  
  
  
  
  
  
  
B
R
C
A
1, 
E
vi-1, 
P
E
B
P
 
rs2701109 
12 
114671825 
0.52 
T/A
 
0.52 
intergenic 
R
B
M
19(dist=267649), 
TB
X
5(dist=119910) 
  
  
  
  
  
  
  
  
5 altered 
m
otifs 
rs10850292 
12 
114672508 
0.47 
C
/A
 
0.23 
intergenic 
R
B
M
19(dist=268332), 
TB
X
5(dist=119227) 
  
  
  
  
  
  
  
  
7 altered 
m
otifs 
rs1247943 
12 
114673421 
0.53 
G
/A
 
0.52 
intergenic 
R
B
M
19(dist=269245), 
TB
X
5(dist=118314) 
  
  
  
  
  
  
  
  
R
FX
5 
  
 
125 x 
rs1247942 
12 
114673723 
0.96 
G
/C
 
0.37 
intergenic 
R
B
M
19(dist=269547), 
TB
X
5(dist=118012) 
  
  
  
  
  
  
  
  
8 altered 
m
otifs 
rs2555015 
12 
114673774 
0.64 
T/C
 
0.47 
intergenic 
R
B
M
19(dist=269598), 
TB
X
5(dist=117961) 
  
  
  
  
  
  
  
  
N
kx2, 
P
bx3 
rs2701108 
12 
114674261 
1 
T/C
 
0.36 
intergenic 
R
B
M
19(dist=270085)
, TB
X5(dist=117474) 
  
  
  
  
  
  
  
  
4 altered 
m
otifs 
rs1270886 
12 
114676470 
0.54 
C
/T 
0.57 
intergenic 
R
B
M
19 
(dist=272294), 
TB
X
5(dist=115265) 
  
  
  
  
  
K
562 
  
  
N
R
S
F 
rs1265496 
12 
114676983 
0.55 
C
/T 
0.43 
intergenic 
R
B
M
19(dist=272807), 
TB
X
5(dist=114752) 
  
  
  
  
  
  
  
  
P
ax-4 
rs2555014 
12 
114677491 
0.55 
G
/T 
0.43 
intergenic 
R
B
M
19(dist=273315), 
TB
X
5(dist=114244) 
  
  
  
  
  
  
  
  
H
oxb6, 
N
R
S
F, 
P
dx1 
rs2555013 
12 
114678318 
0.56 
T/C
 
0.5 
intergenic 
R
B
M
19(dist=274142), 
TB
X
5(dist=113417) 
  
  
  
  
  
  
  
  
4 altered 
m
otifs 
rs7980132 
12 
114678673 
0.41 
A
/G
 
0.19 
intergenic 
R
B
M
19(dist=274497), 
TB
X
5(dist=113062) 
  
  
  
  
  
  
  
  
  
rs2555012 
12 
114678725 
0.52 
C
/T 
0.44 
intergenic 
R
B
M
19(dist=274549), 
TB
X
5(dist=113010) 
  
  
  
  
  
  
O
steobl 
  
G
R
,R
X
R
A
 
rs2252414 
12 
114679137 
0.52 
G
/A
 
0.44 
intergenic 
R
B
M
19(dist=274961), 
TB
X
5(dist=112598) 
  
  
  
  
  
  
  
  
12 
altered 
m
otifs 
rs1950090 
12 
114680189 
0.42 
A
/G
 
0.58 
intergenic 
R
B
M
19(dist=276013), 
TB
X
5(dist=111546) 
  
  
  
B
C
L3, 
U
S
F1 
  
K
562 
H
FF-
M
yc, 
N
T2-D
1 
  
10 
altered 
m
otifs 
rs11067013 
12 
114681027 
0.41 
C
/T 
0.19 
intergenic 
R
B
M
19(dist=276851), 
TB
X
5(dist=110708) 
  
  
  
  
  
  
  
  
4 altered 
m
otifs 
  
 
126 x 
rs1270885 
12 
114681552 
0.51 
A
/G
 
0.44 
intergenic 
R
B
M
19(dist=277376), 
TB
X
5(dist=110183) 
  
  
  
  
  
  
  
  
C
D
P
,Irx,
R
X
R
A
 
rs1247940 
12 
114682651 
0.52 
T/C
 
0.44 
intergenic 
R
B
M
19(dist=278475), 
TB
X
5(dist=109084) 
  
  
  
  
  
  
  
  
P
ax-5 
rs34388546 
12 
114683214 
0.41 
C
/T 
0.19 
intergenic 
R
B
M
19(dist=279038), 
TB
X
5(dist=108521) 
  
  
  
  
  
H
1 
  
  
Irx 
rs2252923 
12 
114683320 
0.48 
A
/G
 
0.42 
intergenic 
R
B
M
19(dist=279144), 
TB
X
5(dist=108415) 
  
  
  
  
  
H
1 
  
  
H
N
F4, 
P
ax-2, 
R
X
R
A
 
rs2252924 
12 
114683323 
0.51 
C
/A
 
0.43 
intergenic 
R
B
M
19(dist=279147), 
TB
X
5(dist=108412) 
  
  
  
  
  
H
1 
  
  
P
ax-2 
rs1247938 
12 
114683568 
0.52 
G
/A
 
0.44 
intergenic 
R
B
M
19(dist=279392), 
TB
X
5(dist=108167) 
  
  
  
C
TC
F, 
R
A
D
21 
  
  
12 cell 
types 
  
N
R
S
F, 
S
pz1 
rs1269789 
12 
114684542 
0.52 
T/C
 
0.44 
intergenic 
R
B
M
19(dist=280366), 
TB
X
5(dist=107193) 
  
  
  
  
  
  
  
  
Irx 
rs2253207 
12 
114685437 
0.51 
T/C
 
0.44 
intergenic 
R
B
M
19(dist=281261), 
TB
X
5(dist=106298) 
  
  
  
  
  
  
  
  
N
kx2 
rs1270884 
12 
114685571 
0.54 
A
/G
 
0.5 
intergenic 
R
B
M
19(dist=281395), 
TB
X
5(dist=106164) 
  
  
  
  
  
  
  
  
S
R
F, 
TFIIA
 
rs4007267 
12 
114685668 
0.45 
A
/T 
N
A
 
intergenic 
R
B
M
19(dist=281492),
TB
X
5(dist=106067) 
  
  
  
  
  
  
  
  
21 
altered 
m
otifs 
rs2555004 
12 
114686645 
0.58 
G
/A
 
0.49 
intergenic 
R
B
M
19(dist=282469), 
TB
X
5(dist=105090) 
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12. LIST OF ABBREVIATIONS 
58C 1958 Birth Cohort 
95%CI 95% Confidence Intervals 
APC Adenomatous Polyposis Coli 
AspECT Aspirin Esomeprazole Chemoprevention Trial 
BE Barrett’s Oesophagus 
BEACON/BEAGESS Barrett's and Esophageal Adenocarcinoma Consortium 
BMI Body Mass Index 
CEU population Utah residents with Northern and Western European ancestry 
CFR Colon Cancer Family Registry 
ChOPIN Chemoprevention Of Premalignant Intestinal Neoplasia 
Chr Chromosome 
CI Confidence Interval 
CNV Copy Number Variation 
CoRGI Colorectal Tumour Gene Identification 
dbSNP The Single Nucleotide Polymorphism Database 
DHH Desert Hedgehog 
dNDP Deoxyribonucleotide Diphosphate 
dNTP Deoxyribonucleotide Triphosphate 
EA Effect Allele 
EAC Oesophageal Adenocarcinoma 
EAGLE Esophageal Adenocarcinoma GenEtics Consortium 
EMT Epithelial to Mesenchymal Transition 
ENCODE Encyclopedia of DNA Elements 
eQTL Expression Quantitative Trait Loci 
FHCRC Fred Hutchinson Cancer Research Centre 
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FRET Fluoresence Resonance Energy Transfer 
gDNA Genomic DNA 
GEJ Gastro-Oesophageal Junction 
GEO Gene Expression Omnibus 
GERD Gastro-Oesophageal Reflux Disease 
GI Gasto-Intestinal 
GLACIER Genetics of LobulAr Carcinoma In situ in EuRope 
GWAS Genome Wide Association Analysis 
H.pylori Helicobacter pylori 
HANDEL Histological Assessment of Neoplasia; Diagnosis and AnaLyses 
hg19 Human Genome build 19 
HGD High Grade Dysplasia 
HH Hedgehog 
HOS Holt-Oram Syndrome 
HOX Homeobox 
IdU Iododeoxyuridine 
IHH Indian Hedgehog 
IM Intestinal Metaplasia 
IPOD Inherited Predisposition of Oesophageal Diseases 
KASPar Kompetitive Allele Specific PCR genotyping system 
LD Linkage Disequilibrium 
LGD Low Grade Dysplasia 
LOH Loss Of Heterozygosity 
LOS Lower Oesophgeal Spincter 
LSBE Long Segment Barrett’s Oesophagus 
MAF Minor Allele Frequency 
MALDI-TOF Matrix Assisted Laser Desorption/Ionization-Time Of Flight 
MAPK Mitogen-Activated Protein Kinase 
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MCS Metaplasia-dysplasia-adenocarcinoma sequence 
MREC Multicentre Research Ethics Committee 
NCBI National Center for Biotechnology Information 
NCDS The National Child Development Study 
NEA Non-Effect Allele 
NHS National Health Service 
NSAID Non-Steroidal Anti-Inflammatory Drug 
OR Odds Ratio 
PC Principal Component 
PCA Principal component analysis 
PCR Polymerase Chain Reaction 
PoBI People of the British Isles 
PPI Proton Pump Inhibitors 
QC Quality Control 
RA Retinoic Acid 
SAP Shrimp Alkaline Phospatase 
SBE Single Base Extension 
SE Standard Error 
SHH Sonic Hedgehog 
SNAP SNP Annotation and Proxy Search 
SNP Single Nucleotide Polymorphism 
SSBE Short Segment Barrett’s Oesophagus 
TGFβ Transforming Growth Factor β 
TOF Tetralogy of Fallot 
UKBS National Blood Service 
UKREP1 UK Replication 1 
UKREP2 UK Replication 2 
UKREP3 UK Replication 3 
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UOS Upper Oesophageal Sphincter 
WHR Waist-Hip Ratio 
WTCCC2 Wellcome Trust Case Control Consortium 2 
WTCHG Wellcome Trust Centre for Human Genetics 
WTSI Wellcome Trust Sanger Institute 
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